

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072036 A2

(51) International Patent Classification⁷: **A61K**

(21) International Application Number: PCT/US02/09036

(22) International Filing Date: 11 March 2002 (11.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/275,025 12 March 2001 (12.03.2001) US
60/281,947 5 April 2001 (05.04.2001) US

(71) Applicants (for all designated States except US): **YALE UNIVERSITY** [US/US]; 451 College Street, New Haven, CT 06520 (US). **L2 DIAGNOSTICS, LLC** [US/US]; P.O. Box 9728, New Haven, CO 06536-0728 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FIKRIG, Erol** [US/US]; 101 Coventry Way, Guilford, CT 06437 (US).

KOSKI, Raymond, A. [US/US]; 7 Meetinghouse Lane, Old Lyme, CT 06371 (US). **WANG, Tian** [CN/US]; 550 Prospect Street #2, New Haven, CO 06511 (US).


(74) Agents: **HALEY, James, F., Jr.** et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS COMPRISING WEST NILE VIRUS POLYPEPTIDES



(57) Abstract: This application is directed to compositions and methods comprising isolated and purified West Nile virus polypeptides and immunogenic fragments thereof, nucleic acid molecules encoding them and antibodies specific for such polypeptides or fragments. Such polypeptides and fragments, fusion proteins comprising them and antibodies are useful as vaccines to treat, inhibit or prevent West Nile virus infection or disease, to detect West Nile virus infection and to monitor the course of disease or immunization.

WO 02/072036 A2

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,

IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

COMPOSITIONS AND METHODS COMPRISING
WEST NILE VIRUS POLYPEPTIDES

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit from United
5 States Provisional Application No. 60/275,025, filed
March 12, 2001 and United States Provisional Application
No. 60/281,947, filed April 5, 2001, the disclosures of
which are hereby incorporated by reference in their
entireties.

10 TECHNICAL FIELD OF THE INVENTION

[0002] This invention relates to compositions and
methods for diagnosing West Nile ("WN") virus infection,
conferring immunity to WN virus and for the prevention of
WN virus infections. More particularly, this invention
15 relates to isolated and/or purified polypeptides
(including recombinant, synthetic and fusion proteins
comprising the polypeptides or synthetic peptides) from
WN virus that are useful to detect WN virus infection in
a subject, to nucleic acid molecules encoding the
20 polypeptides and to pharmaceutical compositions
comprising one or more polypeptides of the invention that
elicit an immune response that is effective either to

- 2 -

prevent WN virus infection or to significantly reduce morbidity and mortality from WN virus infection.

[0003] Also within the scope of this invention are antibodies that specifically bind a polypeptide, peptide
5 or fusion protein of the invention and vaccines comprising one or more of the antibodies of this invention. Additionally, this invention includes diagnostic kits comprising one or more of the polypeptides, peptides or fusion proteins described in
10 the invention or antibodies that specifically bind a polypeptide, peptide or fusion protein of the invention.

BACKGROUND OF THE INVENTION

[0004] In the summer of 1999, an outbreak of encephalitis in humans that was associated with
15 mosquitoes occurred in New York City [CDC, *MMWR*, 48, pp. 845-9 (1999); CDC, *MMWR*, 48, pp. 944-6 (1999); D.S. Asnis et al., *Clin Infect Dis*, 30, pp. 413-8 (2000)]. At approximately the same time, American crows began dying in the Northeastern United States, many in Fairfield
20 County, Connecticut. Two reports in December of 1999 demonstrated that these outbreaks in birds and humans were actually due to WN virus transmitted by mosquitoes [R.S. Lanciotti et al., *Science*, 286, pp. 2333-7 (1999); J.F. Anderson et al., *Science*, 286, pp. 2331-3 (1999)].
25 It is clear from these reports that WN virus was the cause of the 1999 outbreak of fatal encephalitis in the Northeastern United States. This is the first reported appearance of WN virus in the Western Hemisphere.

[0005] Future outbreaks of WN virus in the United
30 States are a new and important public health concern. To date, the only method for preventing WN virus infection is spraying large geographic areas with insecticide to

- 3 -

kill mosquito vectors. Spraying is difficult, potentially toxic to humans, requires repeated applications and is incompletely effective. There is no known vaccine against WN virus. Accordingly, there is an
5 urgent need for a vaccine to prevent infection by WN virus.

[0006] West Nile virus is a member of the family Flaviviridae which also includes the Japanese encephalitis virus (JE), Tick-borne encephalitis virus
10 (TBE), dengue virus (including the four serotypes of: DEN-1, DEN-2, DEN-3, and DEN-4), and the family prototype, yellow fever virus (YF). Flavivirus infections are a global public health problem [C.G. Hayes, in The Arboviruses: Epidemiology and Ecology, T.P. Monath, ed., CRC, Boca Raton, FL, vol. 5, chap. 49
15 (1989); M.J. Cardoso, *Br Med Bull*, 54, pp. 395-405 (1998); Z. Hubalek and J. Halouzka, *Emerg Infect Dis*, 5, pp. 643-50 (1999)] with about half of the flaviviruses causing human diseases. These viral pathogens are
20 transmitted by mosquito or tick vectors. Birds, including the American crow, *Corvus brachyrhynchos*, can serve as non-human reservoirs for the virus. In the case of WN virus, the viruses are transmitted to man by mosquitoes and in the Northeastern United States these
25 mosquito vectors are primarily of the genera *Culex* and *Aedes*, particularly *C. pipiens* and *A. vexans*.

[0007] Flaviviruses are the most significant group of arthropod-transmitted viruses in terms of global morbidity and mortality. An estimated one hundred
30 million cases of the most prevalent flaviviral disease, dengue fever, occur annually. Flaviviral disease typically occurs in the tropical and subtropical regions. Increase global population and urbanization coupled with the lack of sustained mosquito control measures, has

- 4 -

distributed the mosquito vectors of flaviviruses throughout the tropics, subtropics, and some temperate areas. As a result over half the world's population is at risk for flaviviral infection. Further, modern jet
5 travel and human migration have raised the potential for global spread of these pathogens.

[0008] West Nile virus infections generally have mild symptoms, although infections can be fatal in elderly and immunocompromised patients. Typical symptoms of mild WN
10 virus infections include fever, headache, body aches, rash and swollen lymph glands. Severe disease with encephalitis is typically found in elderly patients [D.S. Asnis et al., *supra*]. Death can result from effects on the central nervous system. Sixty-two severe cases and
15 seven deaths were attributed to WN virus encephalitis during the 1999 outbreak [CDC, *supra*; CDC, *supra*; D.S. Asnis et al., *supra*]. Although most WN virus infections are mild, concern is particularly heightened by the potentially fatal outcome of this mosquito-transmitted
20 disease.

[0009] The WN virus, like other flaviviruses, is enveloped by host cell membrane and contains the three structural proteins capsid (C), membrane (M), and envelope (E). The E and M proteins are found on the
25 surface of the virion where they are anchored in the membrane. Mature E is glycosylated, whereas M is not, although its precursor, prM, is a glycoprotein. In other flaviviruses, glycoprotein E is the largest structural protein and contains functional domains responsible for
30 cell surface attachment and intraendosomal fusion activities. In some flaviviruses, E protein has been reported to be a major target of the host immune system during a natural infection.

- 5 -

[0010] The flavivirus genome is a single positive-stranded RNA of approximately 10,500 nucleotides containing short 5' and 3' untranslated regions, a single long open reading frame (ORF), a 5' cap, and a
5 nonpolyadenylated 3' terminus. The ten gene products encoded by the single, long ORF are contained in a polyprotein organized in the order, C (capsid), prM/M (membrane), E (envelope), NS1 (nonstructural protein 1), NS2A, NS2B, NS3, NS4A, NS4B, and NS5 [T.J. Chambers
10 et al., *Ann Rev Microbiol*, 44, pp. 649-88 (1990)].

[0011] Viral replication occurs in the cytoplasm of the infected cell and processing of the encoded polyprotein is initiated cotranslationally. Full maturation of viral proteins requires both host and
15 viral-specific proteases. The sites of proteolytic cleavage in the YF virus, which is likely to be predictive of the sites of cleavage in all flaviviruses, have been determined by comparing the nucleotide sequence and the amino terminal sequences of the viral proteins.
20 Subsequent to initial processing of the polyprotein, prM is converted to M during virus release [G. Wengler et al., *J Virol*, 63, pp. 2521-6 (1989)], and anchored C is processed during virus maturation [Nowak et al., *Virology*, 156, pp. 127-37 (1987)]. In some flaviviruses,
25 the envelope glycoprotein (E) is the major virus antigen involved in virus neutralization by specific antibodies.

[0012] The complete or partial genomes of a number of WN virus isolates from the outbreak in the Northeastern United States have been sequenced. The complete sequence
30 of WN virus isolated from a dead Chilean flamingo (WN-NY99) at the Bronx Zoo was deposited in GenBank™ (accession number AF196835) [R.S. Lanciotti et al., *supra*]. The genome of a WN virus isolate from human victims of the New York outbreak (WNV-NY1999) was

- 6 -

sequenced and deposited as GenBank™ accession number
AF202541 [X-Y. Jia et al., *The Lancet*, 354, pp. 1971-2
(1999)]. Partial sequences of isolates from two species
of mosquito, a crow and a hawk from Connecticut are
5 deposited as GenBank™ accession numbers AF206517-
AF206520, respectively [J.F. Anderson et al., *supra*].
Comparative phylogenetic analysis of the NY sequences
with previously reported WN virus sequences indicated a
high degree of homology between the NY isolates and two
10 isolates from Romania and one from Israel [J.F. Anderson
et al., *supra*; X.-Y. Jia et al., *supra*; R.S. Lanciotti
et al., *supra*].

[0013] While flaviviruses exhibit similar structural
features and components, the individual viruses are
15 significantly different at both the sequence and
antigenic levels. Indeed, antigenic distinctions have
been used to define four different serotypes within just
the dengue virus subgroup of the flaviviruses. Infection
of an individual with one dengue serotype does not
20 provide long-term immunity against the other serotypes
and secondary infections with heterologous serotypes are
becoming increasingly prevalent as multiple serotypes co-
circulate in a geographic area. Such secondary
infections indicate that vaccination or prior infection
25 with any one flavivirus may not to provide generalized
protection against other flaviviruses. Helpful reviews
on the history of attempts to develop suitable vaccines,
which have especially focused on the dengue viruses, and
structural features of the envelope (E) protein of
30 flaviviruses are found in S.B. Halstead, *Science*, 239,
pp. 476-81 (1988); W.E. Brandt, *J Infect Disease*, 162,
pp. 577-83 (1990); T. J. Chambers et al., *Ann Rev*
Microbiol, 44, pp. 649-88 (1990); C. W. Mandl et al.,
Virology, 63, pp. 564-71 (1989); and E.A. Henchal and

- 7 -

J.R. Putnak, *Clin Microbiol Rev*, 3, pp. 376-96 (1990).

[0014] Despite decades of research effort, especially focusing on dengue disease, no safe and effective vaccine against any of the flaviviruses has been developed.

5 Currently, spraying programs utilizing insecticides are the principal means for controlling the spread of WN virus. However, there are significant concerns about the toxic effects of repeated exposure to insecticides. Further, spraying does not provide complete coverage of
10 mosquito breeding areas or eradication of mosquitoes. Accordingly, there is an urgent need for WN virus antigens for use in a vaccine and to detect the presence of a protective immune response.

SUMMARY OF THE INVENTION

15 [0015] The present invention addresses the need for a vaccine to protect against WN virus by providing compositions and methods for detecting WN virus infection, conferring and detecting WN virus immunity and for preventing or reducing the spread of WN virus.
20 Particularly, this invention provides compositions and methods comprising killed virus particles or live, infectious, attenuated viruses that are capable of eliciting the production of neutralizing or protective antibodies against WN virus. More particularly, this
25 invention provides compositions and methods comprising purified WN virus proteins, or immunogenic fragments thereof, that are capable of eliciting the production of neutralizing or protective antibodies against WN virus. The invention further provides nucleic acid molecules
30 encoding the polypeptides in the compositions and methods of the present invention.

[0016] In preferred embodiments, these compositions are derived from WN viral isolates from the Northeastern United States, and more particularly contain one or more WN virus E proteins or immunogenic fragments thereof.

5 This invention further provides methods for the production and isolation of WN virus polypeptides, preferably either recombinantly or synthetically produced as described in this invention.

[0017] This invention also provides a single or
10 multicomponent vaccine comprising one or more killed or live, infectious, attenuated WN virus particles and/or one or more WN virus polypeptides, preferably derived from WN viral isolates from the Northeastern United States and particularly the polypeptides in the
15 compositions of the present invention. This invention also provides antibodies or antigen-binding portions thereof directed against WN virus polypeptides and immunogenic fragments and compositions and methods comprising the antibodies directed against one or more WN
20 viral proteins or antigen-binding fragments thereof.

[0018] Also within the scope of this invention are diagnostic means and methods characterized by the pharmaceutical compositions of WN virus polypeptides or antibodies of the invention. These means and methods are
25 useful for both the detection of WN virus infection or for the detection of a protective immune response to WN virus infection. The methods are also useful in monitoring the course of immunization against WN virus. In patients previously inoculated with the vaccines of
30 this invention, the detection means and methods disclosed herein are also useful for determining if booster inoculations are appropriate.

BRIEF DESCRIPTION OF THE DRAWINGS

[0019] FIG. 1 is the amino acid sequence of the WNE-121-139 fragment (SEQ ID NO: 3).

[0020] FIG. 2 is the amino acid sequence of the WNE-
5 288-301 fragment (SEQ ID NO: 4).

[0021] FIG. 3 is the amino acid sequence of the random-288-301 peptide (SEQ ID NO: 5).

[0022] FIG. 4 is a diagrammatic representation of the 71 kDa Tr-env fusion protein. Tr, thioredoxin domain;
10 EK, enterokinase cleavage site; WNV, 55 kDa full length sequence of West Nile virus envelope protein; V5, V5 epitopes; His, 3 kDa six histidine-tag sequence; 1, location of WNE-288-301 fragment (SEQ ID NO: 4); 2, location of WNE-121-139 fragment (SEQ ID NO: 3).

15 [0023] FIG. 5 is a Coomassie-blue stained SDS-PAGE gel showing purified, recombinant TR-env fusion protein.

[0024] FIG. 6 depicts the utility of mice as an experimental model organism for WN virus infection and further demonstrates that the purified Tr-env protein is
20 able to elicit a protective antibody response. C3H mice were immunized with Tr-env protein (upper line), or Tr control protein (lower line) and challenged with West Nile virus. Five mice were in each group.

[0025] FIG. 7 shows the results of an ELISA
25 demonstrating the specificity of antibodies generated following inoculation of mice with purified Tr-env protein. Ova, ovalbumin; Ova-random, ovalbumin-

- 10 -

conjugated random-288-301 peptide (SEQ ID NO: 5); Ova-281, ovalcumin-conjugated WNE-288-301 peptide (SEQ ID NO: 4). 100, 1000, and 6000 represent serum dilutions of 1:100, 1:1000 and 1:6000.

5 [0026] FIG. 8 shows an experiment monitoring WN virus infection in mice over a range of inoculation doses.

[0027] FIG. 9 shows the results of a passive immunization experiment using antisera from C3H mice inoculated with either TR-env or TR (control).

10 [0028] FIG. 10 shows the results of a passive immunization experiment using antisera from C3H mice inoculated with either TR-env or TR (control).

DETAILED DESCRIPTION OF THE INVENTION

[0029] In one aspect, this invention provides
15 compositions and methods for detecting WN virus infection, conferring and detecting WN virus immunity and for preventing or reducing the spread of WN virus. More particularly, this invention provides compositions and methods comprising one or more killed or live,
20 infectious, attenuated WN virus particles and/or one or more purified WN virus proteins or immunogenic fragments thereof that elicit the production of neutralizing or protective antibodies against WN virus.

[0030] The killed or live, infectious, attenuated WN
25 virus particles in the compositions of the invention can be generated by any one of many methods known in the art. Specific examples include, but are not limited to, heat treatment to kill purified WN virus particles, passage of WN virus isolates in tissue culture to attenuate

- 11 -

virulence [see e.g. Dunster et al., *J Gen Virol*, 71, pp. 601-7 (1990)], or site-specific mutagenesis [see e.g. Mandl et al., *J Virol*, 74, pp. 9601-9].

[0031] As used herein, the term "polypeptide" is taken
5 to encompass all the polypeptides, peptides, and fusion
proteins described in this invention and refers to any
polymer consisting essentially of amino acids regardless
of its size. Although "protein" is often used in
reference to relatively large polypeptides, and "peptide"
10 is often used in reference to small polypeptides, usage
of these terms in the art overlaps and varies. The term
"polypeptide" as used herein thus refers interchangeably
to peptides, polypeptides, or fusion proteins unless
otherwise noted.

15 [0032] The term "amino acid" refers to a monomeric
unit of a peptide, polypeptide or protein.

[0033] A "substantially pure" polypeptide is a
polypeptide that is free from other WN virus components
with which it is normally associated.

20 [0034] As used herein, a "derivative" of a WN virus
polypeptide is a polypeptide in which the native form has
been modified or altered. Such modifications include,
but are not limited to: amino acid substitutions,
modifications, additions or deletions; alterations in the
25 pattern of lipidation, glycosylation or phosphorylation;
reactions of free amino, carboxyl, or hydroxyl side
groups of the amino acid residues present in the
polypeptide with other organic and non-organic molecules;
and other modifications, any of which may result in
30 changes in primary, secondary or tertiary structure.

[0035] As used herein, a "protective epitope" is
(1) an epitope that is recognized by a protective
antibody, and/or (2) an epitope that, when used to
immunize a human or animal, elicits an immune response

- 12 -

sufficient to confer WN virus immunity or to prevent or reduce the severity for some period of time, of the resulting symptoms. A protective epitope may comprise a T cell epitope, a B cell epitope, or combinations thereof.

[0036] In preferred embodiments, this invention provides methods for the production and isolation of WN virus polypeptides, preferably either recombinantly or synthetically produced as described in this invention.

10 [0037] The preferred compositions and methods of the aforementioned embodiments are characterized by immunogenic polypeptides. As used herein, an "immunogenic polypeptide" is a polypeptide that, when administered to a human or animal, is capable of eliciting a corresponding antibody.

[0038] This invention also provides two novel immunogenic fragments of the WN virus E protein and compositions and methods comprising these peptides. More specifically, this invention provides the WNE-121-139 (SEQ ID NO: 3) peptide and WNE-288-301 peptide (SEQ ID NO: 4).

[0039] Also within the scope of this invention are polypeptides that are at least 75% identical in amino acid sequence to the aforementioned polypeptides. Specifically, the invention includes polypeptides that are at least 80%, 85%, 90% or 95% identical in amino acid sequence to an amino acid sequence set forth herein. The term "percent identity" in the context of amino acid sequence refers to the residues in the two sequences which are the same when aligned for maximum correspondence. There are a number of different algorithms known in the art which can be used to measure sequence similarity or identity. For instance, polypeptide sequences can be compared using NCBI BLASTp.

Alternatively, Fasta, a program in GCG version 6.1. Fasta provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Peterson, 1990).

- 5 **[0040]** In another preferred embodiment, this invention provides a vaccine comprising one or more WN virus polypeptides, preferably the E protein, or one or more antibodies directed against a polypeptide present in a pharmaceutical composition of this invention.
- 10 **[0041]** The preferred compositions and methods of the aforementioned embodiments are characterized by WN virus polypeptides that elicit in treated humans or animals the formation of an immune response. As used herein, an
- 15 "immune response" is manifested by the production of antibodies that recognize the corresponding polypeptide. In an especially preferred embodiment, the compositions and methods of the invention are characterized by WN virus polypeptides or antibodies that confer protection against WN virus infection or disease.
- 20 **[0042]** In another embodiment, this invention provides antibodies directed against a WN virus polypeptide in a pharmaceutical composition of this invention, and pharmaceutically effective compositions and methods comprising those antibodies. The antibodies of this invention are
- 25 those that are specifically reactive with a polypeptide, or derivative thereof, isolated from WN virus as described in this invention. Such antibodies may be used in a variety of applications, including to detect the presence of WN virus antigens, for treatment of WN virus
- 30 infection, and to confer immunity to WN virus infection.
- [0043]** In yet another embodiment, this invention relates to diagnostic means and methods characterized by a WN virus polypeptide or antibody of the invention.

- 14 -

[0044] A further embodiment of this invention provides methods for inducing immunity to WN virus in a host by administering one or more of the polypeptides, preferably derived from the WN virus E protein, or antibodies of this invention. A preferred embodiment of this invention is a method for the prevention or reduction of WN virus infection

[0045] As used herein, a "therapeutically effective amount" of a polypeptide or of an antibody is the amount that, when administered to a human or animal, elicits an immune response that is effective to confer immunity to WN virus infection or to prevent or lessen the severity, for some period of time, of a WN virus infection.

[0046] An antibody of this invention includes antibodies that specifically bind one or more of the WN virus polypeptides, preferably from a strain isolated in the Northeastern United States, as described in this invention.

[0047] As used herein, an "antibody" is an immunoglobulin molecule, or antigen-binding portion thereof, that is immunologically reactive with one or more of the purified WN virus polypeptides described in the present invention and that either was elicited by immunization with a pharmaceutical composition of this invention or was isolated or identified by its reactivity with a purified WN virus polypeptide described in the present invention.

[0048] An "antibody" refers to an intact immunoglobulin or to an antigen-binding portion thereof that competes with the intact antibody for specific binding. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include, *inter alia*, Fab, Fab', F(ab')₂, Fv, dAb, and

- 15 -

complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer
5 specific antigen binding to the polypeptide.

[0049] An Fab fragment is a monovalent fragment consisting of the VL, VH, CL and CH I domains; a F(ab')₂ fragment is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge
10 region; a Fd fragment consists of the VH and CH1 domains; an Fv fragment consists of the VL and VH domains of a single arm of an antibody; and a dAb fragment (Ward et al., Nature 341:544-546, 1989) consists of a VH domain.

[0050] A single-chain antibody (scFv) is an antibody
15 in which a VL and VH regions are paired to form a monovalent molecule via a synthetic linker that enables them to be made as a single protein chain (Bird et al., Science 242:423-426, 1988 and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883, 1988). Diabodies are
20 bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of
25 another chain and creating two antigen binding sites (see e.g., Holliger, P., et al., Proc. Natl. Acad. Sci. USA 90:6444-6448, 1993, and Poljak, R. J., et al., Structure 2:1121-1123, 1994). One or more CDRs may be incorporated into a molecule either covalently or noncovalently to
30 make it an immunoadhesin. An immunoadhesin may incorporate the CDR(s) as part of a larger polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s)

- 16 -

noncovalently. The CDRs permit the immunoadhesin to specifically bind to a particular antigen of interest.

[0051] An antibody may have one or more binding sites. If there is more than one binding site, the binding sites
5 may be identical to one another or may be different. For instance, a naturally-occurring immunoglobulin has two identical binding sites, a single-chain antibody or Fab fragment has one binding site, while a "bispecific" or "bifunctional" antibody has two different binding sites.

10 [0052] The antibody of the invention includes human antibodies and humanized antibodies from non-human animals. The term "human antibody" includes all antibodies that have one or more variable and constant regions derived from human immunoglobulin sequences. In
15 a preferred embodiment, all of the variable and constant domains are derived from human immunoglobulin sequences (a fully human antibody). These antibodies may be prepared in a variety of ways that are known in the art, for example, by isolation from humans infected with WN
20 virus, by immunizing a transgenic non-human animal that produces human immunoglobulin heavy and light chains or using a recombinant combinatorial antibody library of human heavy and light chains. See, e.g., United States Patent 6,150,584 and PCT publication number WO 94/02602,
25 published February 3, 1994.

[0053] Recombinant human antibodies of the invention in addition to the antibodies that recognize the WN virus E protein disclosed herein can be isolated by screening of a recombinant combinatorial antibody library,
30 preferably a scFv phage display library, prepared using human VL and VH cDNAs prepared from mRNA derived from human lymphocytes. Methodologies for preparing and screening such libraries are known in the art. There are commercially available kits for generating phage display

- 17 -

libraries (e.g., the Pharmacia Recombinant Phage Antibody System, catalog no. 27-9400-01; and the Stratagene SurfZAP[™] phage display kit, catalog no. 240612). There are also other methods and reagents that can be used in generating and screening antibody display libraries (see, e.g., Ladner et al. U.S. Pat. No. 5,223,409; Kang et al. PCT Publication No. WO 92/18619; Dower et al. PCT Publication No. WO 91/17271; Winter et al. PCT Publication No. WO 92/20791; Markland et al. PCT Publication No. WO 92/15679; Breitling et al. PCT Publication No. WO 93/01288; McCafferty et al. PCT Publication No. WO 92/01047; Garrard et al. PCT Publication No. WO 92/09690; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum. Antibod. Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; McCafferty et al., Nature (1990) 348:552-554; Griffiths et al. (1993) EMBO J 12:725-734; Hawkins et al. (1992) J. Mol. Biol. 226:889-896; Clackson et al. (1991) Nature 352:624-628; Gram et al. (1992) Proc. Natl. Acad. Sci. USA 89:3576-3580; Garrad et al. (1991) Bio/Technology 9:1373-1377; Hoogenboom et al. (1991) Nuc Acid Res 19:4133-4137; and Barbas et al. (1991) Proc. Natl. Acad. Sci. USA 88:7978-7982.

[0054] A humanized antibody is an antibody that is derived from a non-human species, in which certain amino acids in the framework and constant domains of the heavy and light chains have been mutated so as to avoid or abrogate an immune response in humans. Alternatively, a humanized antibody may be produced by fusing the constant domains from a human antibody to the variable domains of a non-human species. Examples of how to make humanized antibodies may be found in United States Patent Nos. 6,054,297, 5,886,152 and 5,877,293.

- 18 -

[0055] The term "chimeric antibody" refers to an antibody that contains one or more regions from one antibody and one or more regions from one or more other antibodies. In a preferred embodiment, one or more of the CDRs are derived from a human antibody that recognizes the WN virus E protein. In a more preferred embodiment, all of the CDRs are derived from a human antibody that recognizes the WN virus E protein. In another preferred embodiment, the CDRs from multiple human antibodies that recognize the WN virus E protein are mixed and matched in a chimeric antibody. For instance, a chimeric antibody may comprise a CDR1 from the light chain of a first human antibody that recognizes the WN virus E protein may be combined with CDR2 and CDR3 from the light chain of a second human antibody that recognizes the WN virus E protein, and the CDRs from the heavy chain may be derived from a third antibody that recognizes the WN virus E protein. Further, the framework regions may be derived from one of the same antibodies, from one or more different antibodies, such as a human antibody, or from a humanized antibody.

[0056] Fragments or analogs of antibodies can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains. Structural and functional domains can be identified by comparison of the nucleotide and/or amino acid sequence data to public or proprietary sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains that occur in other proteins of known structure and/or function. Methods to identify protein sequences that fold into a known three-

- 19 -

dimensional structure are known. Bowie et al. *Science* 253:164 (1991).

[0057] The WN virus polypeptides described herein are immunologically reactive with antisera generated by immunization with the pharmaceutical compositions of the present invention or following infection with WN virus. Accordingly, they are useful in methods and compositions to detect both immunity to WN virus or prior infection with WN virus.

10 [0058] In addition, because at least some, if not all of the WN virus polypeptides described herein are protective proteins, they are particularly useful in single and multicomponent vaccines against WN virus infection. In this regard, multicomponent vaccines are preferred because such vaccines may be formulated to more closely resemble the immunogens presented by WN virus, and because such vaccines are more likely to confer broad-spectrum protection than a vaccine comprising only a single WN virus polypeptide.

20 [0059] Multicomponent vaccines according to this invention may also contain polypeptides which characterize other vaccines useful for immunization against diseases such as, for example, diphtheria, polio, hepatitis, and measles. Such multicomponent vaccines are typically incorporated into a single composition.

[0060] The preferred compositions and methods of this invention comprise WN virus polypeptides having enhanced immunogenicity. Such polypeptides may result when the native forms of the polypeptides or fragments thereof are modified or subjected to treatments to enhance their immunogenic character in the intended recipient.

30 [0061] Numerous techniques are available and well known to those of skill in the art which may be used, without undue experimentation, to substantially increase

- 20 -

the immunogenicity of the WN virus polypeptides described herein. For example, a WN virus polypeptide used in a pharmaceutical composition or vaccine of this invention may be modified by coupling to dinitrophenol groups or
5 arsanilic acid, or by denaturation with heat and/or SDS. Particularly if the polypeptides are small, chemically synthesized polypeptides, it may be desirable to couple them to an immunogenic carrier. The coupling, of course, must not interfere with the ability of either the
10 polypeptide or the carrier to function appropriately. For a review of some general considerations in coupling strategies, see Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, ed. E. Harlow and D. Lane (1988).

15 [0062] Useful immunogenic carriers are well known in the art. Examples of such carriers are keyhole limpet hemocyanin (KLH); albumins such as bovine serum albumin (BSA) and ovalbumin, PPD (purified protein derivative of tuberculin); red blood cells; tetanus toxoid; cholera
20 toxoid; agarose beads; activated carbon; or bentonite.

[0063] Modification of the amino acid sequence of the polypeptides disclosed herein to generate derivatives with altered lipidation states is also a method which may be used to increase their immunogenicity or alter their
25 biochemical properties. For example, the polypeptides or fragments thereof may be expressed with or without the signal and other sequences that may direct addition of lipid moieties.

[0064] As will be apparent from the disclosure to
30 follow, the polypeptides in the pharmaceutical compositions of this invention may also be prepared with the objective of increasing stability or rendering the molecules more amenable to purification and preparation.

One such technique is to express the polypeptides as fusion proteins comprising other WN virus sequences.

[0065] In accordance with this invention, a derivative of a polypeptide of the invention may be prepared by a variety of methods, including by *in vitro* manipulation of the DNA encoding the native polypeptides and subsequent expression of the modified DNA, by chemical synthesis of derivatized DNA sequences, or by chemical or biological manipulation of expressed amino acid sequences.

10 [0066] For example, derivatives may be produced by substitution of one or more amino acids with a different natural amino acid, an amino acid derivative or non-native amino acid. Those of skill in the art will understand that conservative substitution is preferred, e.g., 3-methyl-histidine may be substituted for histidine, 4-hydroxy-proline may be substituted for proline, 5-hydroxylysine may be substituted for lysine, and the like.

[0067] Furthermore, one of skill in the art will recognize that individual substitutions, deletions or additions which alter, add or delete a single amino acid or a small percentage of amino acids (typically less than 5%, more typically less than 1%) in an encoded sequence are "conservatively modified variations" where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);

- 22 -

- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

5 See also, Creighton (1984) Proteins W.H. Freeman and Co.

[0068] Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics such as substitutions within the following groups: valine, glycine; glycine, alanine; 10 valine, isoleucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. The non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan 15 and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic 20 acid and glutamic acid.

[0069] Other conservative substitutions can be taken from Table 1, and yet others are described by Dayhoff in the Atlas of Protein Sequence and Structure (1988).

[0070] Causing amino acid substitutions which are less 25 conservative may also result in desired derivatives, e.g., by causing changes in charge, conformation or other biological properties. Such substitutions would include for example, substitution of a hydrophilic residue for a hydrophobic residue, substitution of a cysteine or 30 proline for another residue, substitution of a residue having a small side chain for a residue having a bulky side chain or substitution of a residue having a net positive charge for a residue having a net negative charge.

[0071] When the result of a given substitution cannot be predicted with certainty, the derivatives may be readily assayed according to the methods disclosed herein to determine the presence or absence of the desired characteristics. In particular, the immunogenicity, immunodominance and/or protectiveness of a derivative polypeptide used in a pharmaceutical composition of this invention can be readily determined using methods disclosed in the Examples.

10 [0072] In a preferred embodiment of this invention, the WN virus polypeptides described herein are prepared as part of a larger fusion protein. For example, a WN virus polypeptide used in a pharmaceutical composition of this invention may be fused at its N-terminus or
15 C-terminus to a different immunogenic WN virus polypeptide, to a non-WN virus polypeptide or to combinations thereof, to produce fusion proteins comprising the WN virus polypeptide.

[0073] In a preferred embodiment of this invention,
20 fusion proteins comprising a WN virus polypeptide used in a pharmaceutical composition are constructed comprising B cell and/or T cell epitopes from multiple strains of WN virus, each variant differing from another with respect to the locations or sequences of the epitopes within the
25 polypeptide. Such fusion proteins are particularly effective in the induction of immunity against a wide spectrum of WN virus strains.

[0074] In another preferred embodiment of this invention, the WN virus polypeptides used in
30 pharmaceutical compositions are fused to moieties, such as immunoglobulin domains, which may increase the stability and prolong the *in vivo* plasma half-life of the polypeptide. Such fusions may be prepared without undue experimentation according to methods well known to those

- 24 -

of skill in the art, for example, in accordance with the teachings of United States patent 4,946,778, or United States patent 5,116,964. The exact site of the fusion is not critical as long as the polypeptide retains the
5 desired biological activity. Such determinations may be made according to the teachings herein or by other methods known to those of skill in the art.

[0075] It is preferred that the fusion proteins comprising the WN virus polypeptides be produced at the
10 DNA level, e.g., by constructing a nucleic acid molecule encoding the fusion protein, transforming host cells with the molecule, inducing the cells to express the fusion protein, and recovering the fusion protein from the cell culture. Alternatively, the fusion proteins may be
15 produced after gene expression according to known methods.

[0076] The polypeptides of the invention may also be part of larger multimeric molecules which may be produced recombinantly or may be synthesized chemically. Such
20 multimers may also include the polypeptides fused or coupled to moieties other than amino acids, including lipids and carbohydrates.

[0077] Preferably, the multimeric proteins will consist of multiple T or B cell epitopes or combinations
25 thereof repeated within the same molecule, either randomly, or with spacers (amino acid or otherwise) between them.

[0078] In a preferred embodiment of this invention, antigens from WN virus strains isolated in the
30 Northeastern United States are incorporated into a vaccine.

[0079] In another embodiment of this invention, a WN virus polypeptide used in a pharmaceutical composition of this invention, preferably a WN virus polypeptide which

is also a protective WN virus polypeptide, is incorporated into a single component vaccine. In another embodiment of this invention, WN virus polypeptides which are also protective polypeptides are incorporated into a multicomponent vaccine comprising other protective polypeptides. In addition, a multicomponent vaccine may also contain protective polypeptides useful for immunization against other diseases such as, for example, diphtheria, polio, hepatitis, and measles. Such a vaccine, by virtue of its ability to elicit antibodies to a variety of protective WN virus polypeptides, will be effective to protect against WN virus infection by a broad spectrum of WN virus strains, even those that may not express a variant of one or more of the WN virus proteins that is cross-reactive with the polypeptides of one particular strain.

[0080] The multicomponent vaccine may contain a WN virus polypeptide as part of a multimeric molecule in which the various components are covalently associated. Alternatively, it may contain multiple individual components. For example, a multicomponent vaccine may be prepared comprising two or more of the WN virus polypeptides, wherein each polypeptide is expressed and purified from independent cell cultures and the polypeptides are combined prior to or during formulation.

[0081] Alternatively, a multicomponent vaccine may be prepared from heterodimers or tetramers wherein the polypeptides have been fused to immunoglobulin chains or portions thereof. Such a vaccine could comprise, for example, a WNE-121-139 polypeptide (SEQ ID NO: 3) fused to an immunoglobulin heavy chain and a WNE-288-301 polypeptide (SEQ ID NO: 4), fused to an immunoglobulin light chain, and could be produced by transforming a host cell with DNA encoding the heavy chain fusion and DNA

- 26 -

encoding the light chain fusion. One of skill in the art will understand that the host cell selected should be capable of assembling the two chains appropriately.

- Alternatively, the heavy and light chain fusions could be
5. produced from separate cell lines and allowed to associate after purification.

[0082] The desirability of including a particular component and the relative proportions of each component may be determined by using the assay systems disclosed
10 herein, or by using other systems known to those in the art. Most preferably, the multicomponent vaccine will comprise numerous T cell and B cell epitopes of protective WN virus polypeptides.

[0083] This invention also contemplates that a WN
15 virus polypeptide described in this invention, either alone or combined, may be administered to an animal via a liposome delivery system in order to enhance their stability and/or immunogenicity. Delivery of a WN virus polypeptide via liposomes may be particularly
20 advantageous because the liposome may be internalized by phagocytic cells in the treated animal. Such cells, upon ingesting the liposome, would digest the liposomal membrane and subsequently present the polypeptide to the immune system in conjunction with other molecules
25 required to elicit a strong immune response.

[0084] The liposome system may be any variety of unilamellar vesicles, multilamellar vesicles, or stable plurilamellar vesicles, and may be prepared and administered according to methods well known to those of
30 skill in the art, for example in accordance with the teachings of United States patents 4,762,915, 5,000,958, 5,169,637 or 5,185,154. In addition, it may be desirable to express the WN virus polypeptides described in this

- 27 -

invention as lipoproteins, in order to enhance their binding to liposomes.

[0085] Any of the polypeptides used in a pharmaceutical composition of this invention may be used
5 in the form of a pharmaceutically acceptable salt. Suitable acids and bases which are capable of forming salts with the polypeptides of the present invention are well known to those of skill in the art, and include inorganic and organic acids and bases.

10 [0086] According to this invention, we describe a method which comprises the steps of treating a subject, including a human, with a therapeutically effective amount of a WN virus polypeptide, preferably from a WN virus strain isolated in the Northeastern United States,
15 or a fusion protein or a multimeric protein comprising a WN virus polypeptide, in a manner sufficient to confer immunity to WN virus infection or prevent or reduce the severity, for some period of time, of the symptoms of WN virus infection. The polypeptides that are preferred for
20 use in such methods are those that contain protective epitopes. Such protective epitopes may be B cell epitopes, T cell epitopes, or combinations thereof.

[0087] According to another embodiment of this invention, we describe a method which comprises the steps
25 of treating a subject, including a human, with a multicomponent vaccine comprising a therapeutically effective amount of a WN virus polypeptide, or a fusion protein or multimeric protein comprising such polypeptide in a manner sufficient to confer immunity to WN virus
30 infection, or prevent or reduce the severity, for some period of time, of the symptoms of WN virus infection. Again, the polypeptides, fusion proteins and multimeric proteins that are preferred for use in such methods are

those that contain protective epitopes, which may be B cell epitopes, T cell epitopes, or combinations thereof.

[0088] The most preferred polypeptides, fusion proteins and multimeric proteins for use in these compositions and methods are those containing both strong T cell and B cell epitopes. Without being bound by theory, we believe that this is the best way to stimulate high titer anti-bodies that are effective to confer immunity to WN virus infection. Such preferred polypeptides will be internalized by B cells expressing surface immunoglobulin that recognizes the B cell epitope(s). The B cells will then process the antigen and present it to T cells. The T cells will recognize the T cell epitope(s) and respond by proliferating and producing lymphokines which in turn cause B cells to differentiate into antibody producing plasma cells. Thus, in this system, a closed autocatalytic circuit exists which will result in the amplification of both B and T cell responses, leading ultimately to production of a strong immune response which includes high titer antibodies against the WN virus polypeptide.

[0089] One of skill in the art will also understand that it may be advantageous to administer a pharmaceutical composition containing WN virus polypeptide as described in this invention in a form that will favor the production of T-helper cells type 1 (T_H1), which help activate macrophages, and/or T-helper cells type 2 (T_H2), which help B cells to generate antibody responses. Aside from administering epitopes which are strong T cell or B cell epitopes, the induction of T_H1 or T_H2 cells may also be favored by the mode of administration of the polypeptide. For example, a WN virus polypeptide may be administered in certain doses or with particular adjuvants and immunomodulators, for

example with interferon-gamma or interleukin-12 (T_H1 response) or interleukin-4 or interleukin-10 (T_H2 response).

[0090] To prepare the preferred polypeptides for use
5 in a pharmaceutical composition of this invention, in one embodiment, overlapping fragments of WN virus polypeptides are constructed. The polypeptides that contain B cell epitopes may be identified in a variety of ways for example by their ability to (1) remove
10 protective antibodies from polyclonal antiserum directed against the polypeptide or (2) elicit an immune response which is effective to confer immunity to WN virus infection, or prevent or reduce the severity, for some period of time, of the symptoms of WN virus infection.

15 [0091] Alternatively, the polypeptides may be used to produce monoclonal antibodies which are screened for their ability to confer immunity to WN virus infection, or prevent or reduce the severity, for some period of time, of the symptoms of WN virus infection, when used to
20 immunize naive animals. Once a given monoclonal antibody is found to confer protection, the particular epitope that is recognized by that antibody may then be identified.

[0092] As recognition of T cell epitopes is MHC
25 restricted, the polypeptides that contain T cell epitopes may be identified *in vitro* by testing them for their ability to stimulate proliferation and/or cytokine production by T cell clones generated from humans of various HLA types, from the lymph nodes, spleens, or
30 peripheral blood lymphocytes of C3H or other laboratory mice, or from domestic animals.

[0093] In a preferred embodiment of the present invention, a WN virus polypeptide containing a B cell epitope is fused to one or more other immunogenic WN

- 30 -

virus polypeptides containing strong T cell epitopes. The fusion protein that carries both strong T cell and B cell epitopes is able to participate in elicitation of a high titer antibody response effective to confer immunity to WN virus infection.

[0094] Strong T cell epitopes may also be provided by non-WN virus molecules. For example, strong T cell epitopes have been observed in hepatitis B virus core antigen (HBcAg). Furthermore, it has been shown that linkage of one of these segments to segments of the surface antigen of Hepatitis B virus, which are poorly recognized by T cells, results in a major amplification of the anti-HBV surface antigen response, [D.R. Milich et al., *Nature*, 329, pp. 547-49 (1987)].

[0095] Therefore, in yet another preferred embodiment, B cell epitopes of the WN virus polypeptides are fused to segments of HBcAG or to other antigens which contain strong T cell epitopes, to produce a fusion protein that can elicit a high titer antibody response against WN virus antigens. In addition, it may be particularly advantageous to link an WN virus polypeptide for use in a pharmaceutical composition of this invention to a strong immunogen that is also widely recognized, for example tetanus toxoid.

[0096] It will be readily appreciated by one of ordinary skill in the art that the polypeptides in the pharmaceutical compositions of this invention, as well as fusion proteins and multimeric proteins containing them, may be prepared by recombinant means, chemical means, or combinations thereof.

[0097] For example, the polypeptides may be generated by recombinant means using the DNA sequence as set forth in the sequence listing contained herein. DNA encoding variants of the polypeptides in other WN virus strains

- 31 -

may likewise be cloned, e.g., using PCR and oligonucleotide primers derived from the sequence herein disclosed.

[0098] In this regard, it may be particularly desirable to isolate the genes encoding WN virus polypeptides from any isolates that may differ antigenically, i.e., WN virus isolates against which the pharmaceutical compositions described in the present invention which are initially used for vaccine development are ineffective to protect, in order to obtain a broad spectrum of different epitopes which would be useful in the methods and compositions of this invention.

[0099] Oligonucleotide primers and other nucleic acid probes derived from the genes encoding the polypeptides in the pharmaceutical compositions of this invention may also be used to isolate and clone related proteins from other WN virus isolates which may contain regions of DNA sequence homologous to the DNA sequences of the polypeptides described in this invention.

[0100] In a preferred embodiment, the polypeptides used in the pharmaceutical compositions of this invention are produced recombinantly and may be expressed in unicellular hosts. As is well known to one of skill in the art, in order to obtain high expression levels of foreign DNA sequences in a host, the sequences are generally operably linked to transcriptional and translational expression control sequences that are functional in the chosen host. Preferably, the expression control sequences, and the gene of interest, will be contained in an expression vector that further comprises a selection marker.

[0101] The DNA sequences encoding the polypeptides used in the pharmaceutical compositions of this invention may or may not encode a signal sequence. If the

expression host is eukaryotic, it generally is preferred that a signal sequence be encoded so that the mature protein is secreted from the eukaryotic host.

[0102] An amino terminal methionine may or may not be present on the expressed polypeptides in the pharmaceutical compositions of this invention. If the terminal methionine is not cleaved by the expression host, it may, if desired, be chemically removed by standard techniques.

[0103] A wide variety of expression host/vector combinations may be employed in expressing the DNA sequences encoding the WN virus polypeptides used in the pharmaceutical compositions and vaccines of this invention. Useful expression vectors for eukaryotic hosts, include, for example, vectors comprising expression control sequences from SV40, bovine papilloma virus, adenovirus, adeno-associated virus, cytomegalovirus and retroviruses including lentiviruses. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli*, including pBluescript[®], pGEX-2T, pUC vectors, col E1, pCR1, pBR322, PMB9 and their derivatives, pET-15, wider host range plasmids, such as RP4, phage DNAs, e.g., the numerous derivatives of phage lambda, e.g. λ GT10 and λ GT11, and other phages. Useful expression vectors for yeast cells include the 2 μ plasmid and derivatives thereof. Useful vectors for insect cells include pVL 941.

[0104] In addition, any of a wide variety of expression control sequences -- sequences that control the expression of a DNA sequence when operably linked to it -- may be used in these vectors to express the polypeptides used in the pharmaceutical compositions of this invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors.

- 33 -

Examples of useful expression control sequences include, for example, the early and late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC or TRC system, the T3 and T7 promoters, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast α -mating system and other constitutive and inducible promoter sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof.

[0105] In a preferred embodiment, a DNA sequence encoding a WN virus polypeptide used in a pharmaceutical composition of this invention is cloned in the expression vector lambda ZAP[®] II (Stratagene, La Jolla, CA), in which expression from the *lac* promoter may be induced by IPTG.

[0106] In another preferred embodiment, a DNA sequence encoding a WN virus polypeptide, preferably the E protein, that is used in a pharmaceutical composition of this invention is cloned in the pBAD/Thiofusion[™] expression vector, in which expression of the resulting thioredoxin fusion protein from the *araBAD* promoter may be induced by arabinose.

[0107] In yet another preferred embodiment, DNA encoding the WN virus polypeptides used in a pharmaceutical composition of this invention is inserted in frame into an expression vector that allows high level expression of the polypeptide as a glutathione S-transferase fusion protein. Such a fusion protein thus contains amino acids encoded by the vector sequences as well as amino acids of the WN virus polypeptide.

- 34 -

[0108] The term "host cell" refers to one or more cells into which a recombinant DNA molecule is introduced. Host cells of the invention include, but need not be limited to, bacterial, yeast, animal and
5 plant cells. Host cells can be unicellular, or can be grown in tissue culture as liquid cultures, monolayers or the like. Host cells may also be derived directly or indirectly from tissues.

[0109] A wide variety of unicellular host cells are
10 useful in expressing the DNA sequences encoding the polypeptides used in the pharmaceutical compositions of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of *E. coli*, *Pseudomonas*, *Bacillus*, *Streptomyces*, fungi,
15 yeast, insect cells such as *Spodoptera frugiperda* (SF9), animal cells such as CHO and mouse cells, African green monkey cells such as COS 1, COS 7, BSC 1, BSC 40, and BMT 10, and human cells, as well as plant cells.

[0110] A host cell is "transformed" by a nucleic acid
20 when the nucleic acid is translocated into the cell from the extracellular environment. Any method of transferring a nucleic acid into the cell may be used; the term, unless otherwise indicated herein, does not imply any particular method of delivering a nucleic acid
25 into a cell, nor that any particular cell type is the subject of transfer.

[0111] An "expression control sequence" is a nucleic acid sequence which regulates gene expression (i.e., transcription, RNA formation and/or translation).
30 Expression control sequences may vary depending, for example, on the chosen host cell or organism (e.g., between prokaryotic and eukaryotic hosts), the type of transcription unit (e.g., which RNA polymerase must recognize the sequences), the cell type in which the gene

- 35 -

is normally expressed (and, in turn, the biological factors normally present in that cell type).

[0112] A "promoter" is one such expression control sequence, and, as used herein, refers to an array of
5 nucleic acid sequences which control, regulate and/or direct transcription of downstream (3') nucleic acid sequences. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II
10 type promoter, a TATA element.

[0113] A "constitutive" promoter is a promoter which is active under most environmental and developmental conditions. An "inducible" promoter is a promoter which is inactive under at least one environmental or
15 developmental condition and which can be switched "on" by altering that condition. A "tissue specific" promoter is active in certain tissue types of an organism, but not in other tissue types from the same organism. Similarly, a developmentally-regulated promoter is active during some
20 but not all developmental stages of a host organism.

[0114] Expression control sequences also include distal enhancer or repressor elements which can be located as much as several thousand base pairs from the start site of transcription. They also include sequences
25 required for RNA formation (e.g., capping, splicing, 3' end formation and poly-adenylation, where appropriate); translation (e.g., ribosome binding site); and post-translational modifications (e.g., glycosylation, phosphorylation, methylation, prenylation, and the like).

30 [0115] The term "operably linked" refers to functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs

- 36 -

transcription of the nucleic acid corresponding to the second sequence.

[0116] It should of course be understood that not all vectors and expression control sequences will function
5 equally well to express the WN virus polypeptides mentioned herein. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without
10 undue experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must be replicated in it. The vector's copy number, the ability to control that copy number, the ability to
15 control integration, if any, and the expression of any other proteins encoded by the vector, such as antibiotic or other selection markers, should also be considered.

[0117] In selecting an expression control sequence, a variety of factors should also be considered. These
20 include, for example, the relative strength of the promoter sequence, its controllability, and its compatibility with the DNA sequence of the peptides described in this invention, particularly with regard to potential secondary structures. Unicellular hosts should
25 be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded for by the DNA sequences encoding the proteins used in a pharmaceutical composition of this invention, their secretion characteristics, their ability to fold the
30 polypeptide correctly, their fermentation or culture requirements, and the ease of purification from them of the products coded for by the DNA sequences.

[0118] Within these parameters, one of skill in the art may select various vector/expression control

- 37 -

sequence/host combinations that will express the DNA sequences encoding the products used in the pharmaceutical compositions of this invention on fermentation or in other large scale cultures.

5 [0119] The polypeptides described in this invention may be isolated from the fermentation or cell culture and purified using any of a variety of conventional methods including: liquid chromatography such as normal or reversed phase, using HPLC, FPLC and the like; affinity
10 chromatography (such as with inorganic ligands or monoclonal antibodies); size exclusion chromatography; immobilized metal chelate chromatography; gel electrophoresis; and the like. One of skill in the art may select the most appropriate isolation and
15 purification techniques without departing from the scope of this invention. If the polypeptide is membrane bound or suspected of being a lipoprotein, it may be isolated using methods known in the art for such proteins, e.g., using any of a variety of suitable detergents.

20 [0120] In addition, the polypeptides of the invention may be generated by any of several chemical techniques. For example, they may be prepared using the solid-phase synthetic technique originally described by R. B. Merrifield, *J Am Chem Soc*, 83, pp. 2149-54 (1963), or
25 they may be prepared by synthesis in solution. A summary of peptide synthesis techniques may be found in E. Gross & H. J. Meinhofer, 4 The Peptides: Analysis, Synthesis, Biology; Modern Techniques Of Peptide And Amino Acid Analysis, John Wiley & Sons, (1981) and
30 M. Bodanszky, Principles Of Peptide Synthesis, Springer-Verlag (1984).

[0121] Typically, these synthetic methods comprise the sequential addition of one or more amino acid residues to a growing peptide chain. Often peptide coupling agents

- 38 -

are used to facilitate this reaction. For a recitation of peptide coupling agents suitable for the uses described herein see M. Bodansky, *supra*. Normally, either the amino or carboxyl group of the first amino acid residue is protected by a suitable, selectively removable protecting group. A different protecting group is utilized for amino acids containing a reactive side group, e.g., lysine. A variety of protecting groups known in the field of peptide synthesis and recognized by conventional abbreviations therein, may be found in T. Greene, Protective Groups In Organic Synthesis, Academic Press (1981).

[0122] According to another embodiment of this invention, antibodies directed against a WN virus polypeptide are generated. Such antibodies are immunoglobulin molecules or portions thereof that are immunologically reactive with a polypeptide of the present invention. It should be understood that the antibodies of this invention include antibodies immunologically reactive with fusion proteins and multimeric proteins comprising a WN virus polypeptide.

[0123] Antibodies directed against a WN virus polypeptide may be generated by a variety of means including immunizing a mammalian host with WN virus extract or infection with WN virus, or by immunization of a mammalian host with a WN virus polypeptide of the present invention. Such antibodies may be polyclonal or monoclonal; it is preferred that they are monoclonal. Methods to produce polyclonal and monoclonal antibodies are well known to those of skill in the art. For a review of such methods, see Antibodies, A Laboratory Manual, *supra*, and D.E. Yelton, et al., *Ann Rev Biochem*, 50, pp. 657-80 (1981). Determination of immunoreactivity with a WN virus polypeptide used in a pharmaceutical

- 39 -

composition of this invention may be made by any of several methods well known in the art, including by immunoblot assay and ELISA.

[0124] An antibody of this invention may also be a hybrid molecule formed from immunoglobulin sequences from different species (e.g., mouse and human) or from portions of immunoglobulin light and heavy chain sequences from the same species. It may be a molecule that has multiple binding specificities, such as a bifunctional antibody prepared by any one of a number of techniques known to those of skill in the art including: the production of hybrid hybridomas; disulfide exchange; chemical cross-linking; addition of peptide linkers between two monoclonal antibodies; the introduction of two sets of immunoglobulin heavy and light chains into a particular cell line; and so forth.

[0125] The antibodies of this invention may also be human monoclonal antibodies produced by any of the several methods known in the art. For example, human monoclonal antibodies may be produced by immortalized human cells, by SCID-hu mice or other non-human animals capable of producing "human" antibodies, by the expression of cloned human immunoglobulin genes, by phage-display, or by any other method known in the art.

[0126] In addition, it may be advantageous to couple the antibodies of this invention to toxins such as diphtheria, pseudomonas exotoxin, ricin A chain, gelonin, etc., or antibiotics such as penicillins, tetracyclines and chloramphenicol.

[0127] In sum, one of skill in the art, provided with the teachings of this invention, has available a variety of methods which may be used to alter the biological properties of the antibodies of this invention including methods which would increase or decrease the stability or

- 40 -

half-life, immunogenicity, toxicity, affinity or yield of a given antibody molecule, or to alter it in any other way that may render it more suitable for a particular application.

5 [0128] One of skill in the art will understand that antibodies directed against a pharmaceutical composition of the invention may have utility in prophylactic compositions and methods directed against WN virus infection. For example, the level of WN virus in
10 infected mosquitoes may be decreased by allowing them to feed on the blood of animals immunized with a pharmaceutical composition or vaccine of this invention.

 [0129] The antibodies of this invention also have a variety of other uses. For example, they are useful as
15 reagents to screen for expression of the WN virus polypeptides, either in libraries constructed from WN virus DNA or from other samples in which the proteins may be present. Moreover, by virtue of their specific binding affinities, the antibodies of this invention are
20 also useful to purify or remove polypeptides from a given sample, to block or bind to specific epitopes on the polypeptides and to direct various molecules, such as toxins, to mosquitoes serving as vectors for WN virus.

 [0130] To screen the pharmaceutical compositions,
25 vaccines and antibodies of this invention for their ability to confer protection against WN virus infection or their ability to reduce the severity or duration of the attendant symptoms, mice are preferred as an animal model. Of course, while any animal that is susceptible
30 to WN virus infection may be useful, mice are a well-known and particularly convenient model. Thus, by administering a particular WN virus polypeptide or anti-WN virus polypeptide antibody to mice, one of skill in the art may determine without undue experimentation

- 41 -

whether that polypeptide or antibody would be useful in the methods and compositions claimed herein.

[0131] The administration of the WN virus polypeptide or antibody of this invention to the animal may be accomplished by any of the methods disclosed herein or by a variety of other standard procedures. For a detailed discussion of such techniques, see Antibodies, A Laboratory Manual, *supra*. Preferably, if a polypeptide is used, it will be administered with a pharmaceutically acceptable adjuvant, such as complete or incomplete Freund's adjuvant, RIBI (muramyl dipeptides) or ISCOM (immunostimulating complexes). Such adjuvants may protect the polypeptide from rapid dispersal by sequestering it in a local deposit, or they may contain substances that stimulate the host to secrete factors that are chemotactic for macrophages and other components of the immune system. Preferably, if a polypeptide is being administered, the immunization schedule will involve two or more administrations of the polypeptide, spread out over several weeks.

[0132] Once the pharmaceutical compositions, vaccines or antibodies of this invention have been determined to be effective in the screening process, they may then be used in a therapeutically effective amount in pharmaceutical compositions and methods to confer immunity to WN virus infection in humans and animals and to prevent or reduce the transmission of WN virus from non-human host animals.

[0133] The pharmaceutical compositions of this invention may be in a variety of conventional depot forms. These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, liposomes, capsules, suppositories, injectable and infusible solutions. The

preferred form depends upon the intended mode of administration and prophylactic application.

[0134] Such dosage forms may include pharmaceutically acceptable carriers and adjuvants which are known to those of skill in the art. These carriers and adjuvants include, for example, RIBI, ISCOM, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances, such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, and polyethylene glycol. Adjuvants for topical or gel base forms may be selected from the group consisting of sodium carboxymethylcellulose, polyacrylates, polyoxyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wood wax alcohols.

[0135] The vaccines and compositions of this invention may also include other components or be subject to other treatments during preparation to enhance their immunogenic character or to improve their tolerance in patients.

[0136] Compositions comprising an antibody of this invention may be administered by a variety of dosage forms and regimens similar to those used for other passive immunotherapies and well known to those of skill in the art. Generally, the WN virus polypeptides may be formulated and administered to the patient using methods and compositions similar to those employed for other pharmaceutically important polypeptides (e.g., the vaccine against hepatitis).

- 43 -

[0137] Any pharmaceutically acceptable dosage route, including parenteral, intravenous, intramuscular, intralesional or subcutaneous injection, may be used to administer the polypeptide or antibody composition. For example, the composition may be administered to the patient in any pharmaceutically acceptable dosage form including those which may be administered to a patient intravenously as bolus or by continued infusion over a period of hours, days, weeks or months, intramuscularly -- including paravertebrally and periarticularly -- subcutaneously, intracutaneously, intra-articularly, intrasynovially, intrathecally, intralesionally, periostally or by oral or topical routes. Preferably, the compositions of the invention are in the form of a unit dose and will usually be administered to the patient intramuscularly.

[0138] The pharmaceutical compositions, vaccines or antibodies of this invention may be administered to the patient at one time or over a series of treatments. The most effective mode of administration and dosage regimen will depend upon the level of immunogenicity, the particular composition and/or adjuvant used for treatment, the severity and course of the expected infection, previous therapy, the patient's health status and response to immunization, and the judgment of the treating physician.

[0139] For example, in an immunocompetent patient, the more highly immunogenic the polypeptide, the lower the dosage and necessary number of immunizations. Similarly, the dosage and necessary treatment time will be lowered if the polypeptide is administered with an adjuvant. Generally, the dosage will consist of 10 μ g to 100 mg of the purified polypeptide, and preferably, the dosage will

- 44 -

consist of 10-1000 µg. Generally, the dosage for an antibody will be 0.5 mg-3.0 g.

[0140] In a preferred embodiment of this invention, the WN virus polypeptide is administered with an
5 adjuvant, in order to increase its immunogenicity. Useful adjuvants include RIBI, and ISCOM, simple metal salts such as aluminum hydroxide, and oil based adjuvants such as complete and incomplete Freund's adjuvant. When an oil based adjuvant is used, the polypeptide usually is
10 administered in an emulsion with the adjuvant.

[0141] In yet another preferred embodiment, *E. coli* expressing proteins comprising an WN virus polypeptide are administered orally to non-human animals according to methods known in the art, to confer immunity to WN virus
15 infection and to prevent or reduce the transmission of WN virus from non-human animals. For example, a palatable regimen of bacteria expressing a WN virus polypeptide, alone or in the form of a fusion protein or multimeric protein, may be administered with animal food to be
20 consumed by wild birds or other animals that act as alternative hosts for WN virus.

[0142] Ingestion of such bacteria may induce an immune response comprising both humoral and cell-mediated components. See J.C. Sadoff et al., *Science*, 240,
25 pp. 336-38 (1988); K.S. Kim et al., *Inf Immun*, 57, pp. 2434-40 (1989); M. Dunne et al., *Inf Immun*, 63, pp. 1611-4 (1995); E. Fikrig et al., *J Infec Dis*, 164, 1224-7 (1991).

[0143] Moreover, the level of pathogens in mosquitoes
30 feeding on such animals may be lessened or eliminated, thus inhibiting transmission to the next animal.

[0144] According to yet another embodiment, the WN virus polypeptides used in the pharmaceutical compositions of this invention, preferably, are useful as

diagnostic agents for detecting immunity to WN virus or prior infection with WN virus. The polypeptides are capable of binding to antibody molecules produced in animals, including humans, that have been exposed to WN virus antigens as a result of infection with WN virus or vaccination with a pharmaceutical composition of this invention. The detection of WN virus antigens is evidence of prior exposure to WN virus. Such information is an important aid in the diagnosis of WN virus infection.

[0145] Such diagnostic agents may be included in a kit which may also comprise instructions for use and other appropriate reagents, preferably a means for detecting when the polypeptide or antibody is bound. For example, the polypeptide or antibody may be labeled with a detection means that allows for the detection of the polypeptide when it is bound to an antibody, or for the detection of the antibody when it is bound to WN virus or an antigen thereof.

[0146] The detection means may be a fluorescent labeling agent such as fluorescein isocyanate (FIC), fluorescein isothiocyanate (FITC), and the like, an enzyme, such as horseradish peroxidase (HRP), glucose oxidase or the like, a radioactive element such as ^{125}I or ^{51}Cr that produces gamma ray emissions, or a radioactive element that emits positrons which produce gamma rays upon encounters with electrons present in the test solution, such as ^{11}C , ^{15}O , or ^{13}N . Binding may also be detected by other methods, for example via avidin-biotin complexes.

[0147] The linking of the detection means is well known in the art. For instance, monoclonal antibody molecules produced by a hybridoma can be metabolically labeled by incorporation of radioisotope-containing amino

acids in the culture medium, or polypeptides may be conjugated or coupled to a detection means through activated functional groups.

[0148] The diagnostic kits of the present invention
5 may be used to detect the presence of anti-WN virus antibodies in a body fluid sample such as serum, plasma or urine. Thus, in preferred embodiments, a WN virus polypeptide or an antibody of the present invention is bound to a solid support typically by adsorption from an
10 aqueous medium. Useful solid matrices are well known in the art, and include crosslinked dextran; agarose; polystyrene; polyvinylchloride; cross-linked polyacrylamide; nitrocellulose or nylon-based materials; tubes, plates or the wells of microtiter plates. The
15 polypeptides or antibodies of the present invention may be used as diagnostic agents in solution form or as a substantially dry powder, e.g., in lyophilized form.

[0149] WN virus polypeptides and antibodies directed against those polypeptides provide much more specific
20 diagnostic reagents than whole WN virus and thus may alleviate such pitfalls as false positive and false negative results.

[0150] One skilled in the art will realize that it may also be advantageous in the preparation of detection
25 reagents to utilize epitopes from more than one WN virus protein or more than one WN virus isolate and antibodies directed against such epitopes.

[0151] The skilled artisan also will realize that it may be advantageous to prepare a diagnostic kit
30 comprising diagnostic reagents to detect WN virus as well as pathogens found in the same mosquito vector, for example other flaviviruses which are known to exhibit similar symptoms, and instructions for their use.

- 47 -

[0152] The compositions and methods comprising the polypeptides and antibodies of the present invention may also be useful for prevention of infection by other strains of WN virus which may express proteins sharing
5 amino acid sequence or conformational similarities with the WN virus polypeptides of the present invention.

[0153] Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising," will be understood to imply the inclusion
10 of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

[0154] In order that this invention may be better understood, the following examples are set forth. These examples are for purposes of illustration only, and are
15 not to be construed as limiting the scope of the invention in any manner.

Example I - Isolation of WN virus in Connecticut

[0155] We obtained several WN virus isolates from mosquitoes and birds in Connecticut. Mosquitoes were
20 captured in dry ice-baited Centers for Disease Control miniature light traps. One mosquito trap was placed at each location per night; the numbers of traps per site ranged from 1 to 6. Mosquitoes were transported alive to the laboratory where they were identified and grouped
25 (pooled) according to species, collecting site, and date. The number of mosquitoes per pool ranged from 1 to 50. The total number of mosquitoes by species that were collected in 14 towns in Fairfield County, CT, and tested for virus from 6 September through 14 October 1999:
30 *Aedes vexans*, 1688; *Ae. cinereus*, 172; *Ae. trivittatus*, 131; *Ae. taeniorhynchus*, 123; *Ae. sollicitans*, 109; *Ae. cantator*, 63; *Ae. triseriatus*, 28; *Ae. japonicus*, 19; *Ae. canadensis*, 1; *Anopheles punctipennis*, 82; *An.*

- 48 -

quadrimaculatus, 4; *An. walkeri*, 2; *Coquillettidia perturbans*, 15; *Culex pipiens*, 744; *Cx. restuans*, 27; *Cx. erraticus*, 4; *Cx. territans*, 1; *Culiseta melanura*, 76; *Cs. morsitans*, 1; *Psorophora ferox*, 4; and *Uranotaenia sapphirina*, 104. Mosquitoes were stored at -80°C until tested for virus. Additionally, we obtained isolated West Nile virus from mosquitoes collected in New York City.

[0156] Most dead birds were collected by state or town personnel in Connecticut and sent to the Pathobiology Department at the University of Connecticut, Storrs, where they were examined for postmortem and nutritional condition, gross lesions, and microscopic evidence indicative of encephalitis. Brain tissue from birds with presumed encephalitis was frozen at -70°C and then sent to the Connecticut Agricultural Experiment Station, New Haven, for virus testing. Connecticut towns from which dead crows were collected and virus isolated from brain tissues (number of isolates in parentheses): Bridgeport (1), Darien (1), Fairfield (4), Greenwich (3), Hamden (1), Madison (1), Milford (1), New Canaan (1), New Haven (3), North Haven (1), Norwalk (1), Redding (1), Stamford (5), Stratford (1), Weston (1), Westport (1), and Woodbridge (1).

[0157] For viral isolation from mosquitoes, frozen pools were thawed, triturated in tissue grinders or mortars with pestles in 1 to 1.5 ml of phosphate-buffered saline ("PBS") containing 0.5% gelatin, 30% rabbit serum, antibiotic, and antimycotic. After centrifugation for 10 min at 520 x g, 100 µl samples of each pool of mosquitoes were inoculated onto a monolayer of Vero cells grown in a 25-cm² flask at 37°C in 5% CO₂. Cells were examined microscopically for cytopathologic effect for up to 7 days after inoculation.

- 49 -

[0158] For viral isolation from bird brain tissue samples, a 10% suspension of each sampled brain tissue was prepared in 1.5 ml of PBS by triturating with a mortar and pestle as described above for mosquito samples except that Alundum[®] was added to facilitate homogenization of tissue. Two to seven tissue samples from each brain were tested for virus as follows. Suspensions were centrifuged at 520 x g for 10 min. The supernatant of each sample was then passed through a 0.22- μ m filter before inoculation of a 100- μ l sample onto a monolayer of Vero cells. Cells were grown in a 25-cm² flask at 37°C in 5% CO₂ and examined for cytopathologic effect for up to 7 days after inoculation.

[0159] Viral isolates were tested in an ELISA against reference antibodies to six viruses, in three families, isolated from mosquitoes in North America. The antibodies were prepared in mice and provided by the World Health Organization Center for Arbovirus Research and Reference, Yale Arbovirus Research Unit, Department of Epidemiology and Public Health, Yale University School of Medicine. The antibodies were to Eastern Equine Encephalomyelitis and Highlands J, Cache Valley, LaCrosse, Jamestown Canyon, and St. Louis Encephalitis viruses.

25 Example II - PCR amplification of DNA encoding the WN virus envelope protein

[0160] We grew the Connecticut WN virus isolate 2741 (GenBank[™] Accession No. AF206518) as described above in Vero cells which were subsequently scraped from the bottom of the flask and centrifuged at 4500 x g for 10 min. We discarded the supernatant and extracted RNA from the pellet using the RNeasy[®] mini protocol (Qiagen), eluting the column twice with 40 μ l of ribonuclease-free

- 50 -

water. We used two microliters of each eluate in a 50- μ l reverse transcription-polymerase chain reaction (RT-PCR) with the SuperScript® one step RT-PCR system (Life Technologies), following the manufacturer's protocol. We
5 designed the PCR primers WN-233F (5'-GACTGAAGAGGGCAATGTTGAGC-3'; SEQ ID: 1) and WN-1189R (5'-GCAATAACTGCGGACYTCTGC-3'; SEQ ID: 2) specifically to amplify envelope protein sequences from WN viruses based on an alignment of six flavivirus isolates listed in
10 GenBank™ [accession numbers: M16614; M73710; D00246; M12294; AF130362; AF130363]. We purified the PCR products with the QIAquick PCR Purification Kit® (Qiagen) following the manufacturer's protocol. The amplified DNA and sequenced by the Sanger method at the Keck
15 Biotechnology Center at Yale University, New Haven, CT. We confirmed that this sequence corresponded to the envelope protein encoding sequence by alignment with the envelope protein encoding sequence from other flavivirus isolates using the ClustalX 1.64B program [J.D. Thompson, et al., *Nucleic Acids Res*, 22, 4673 (1994)]. We further
20 purified the resulting DNA fragments by electrophoresis on a 1% agarose gel, excised the DNA band, and isolated the DNA using the QIAquick Gel Extraction Kit® (Qiagen) following the manufacturer's protocol.

25

Example III - Expression and purification of recombinant WN virus envelope protein

[0161] We expressed the protein encoded by the DNA isolated in Example II in *E. coli* using the pBAD/TOPO™
30 ThioFusion Expression System® (Invitrogen). This system is designed for highly efficient, five minute, one step cloning of PCR amplified DNA into the pBAD/TOPO™ ThioFusion expression vector. Fusion protein expression is inducible with arabinose. Fusion proteins are

- 51 -

expressed with thioredoxin (12 kDa) fused to the N-terminus, and a C-terminal polyhistidine tag. The polyhistidine tag allows fusion proteins to be rapidly purified by nickel affinity column chromatography. An enterokinase cleavage site in the fusion proteins can be used to remove the N-terminal thioredoxin leader.

[0162] We used the pBAD/TOPO ThioFusion Expression System[®] expression system to express and purify West Nile virus envelope protein following the manufacturer's protocol. Specifically, we added the PCR product obtained as described above to a reaction containing the pBAD/Thio-TOPO[™] vector (1 μ l) and sterile water added to a final volume of 5 μ l. We incubated this reaction mix for five minutes at room temperature.

[0163] We transformed One Shot[™] *E. coli* cells (Invitrogen) with the TOPO[™] cloning reaction products by mixing the TOPO[™] cloning reaction with competent cells, incubating the mixture on ice for 30 minutes and then heat shocking the cells for 30 seconds at 42°C. We added 250 μ l of room temperature SOC medium to the cells and incubated at 37°C for 30 minutes. We spread 50 μ l of the transformation mixture on a prewarmed LB plate containing 50 μ g/ml ampicillin and incubated overnight at 37°C. We then performed DNA sequence analysis to confirm that the thioredoxin-envelope protein fusion protein (TR-env; Fig. 4) coding sequences were correct.

[0164] To analyze expression of the recombinant TR-env protein, we grew *E. coli* containing the pBAD-TR-env expression vector in cultures at 37°C with vigorous shaking to an OD₆₀₀ = ~0.5. Prior to protein expression, i.e. at the zero point, we took an aliquot, centrifuged at maximum speed, removed the supernatant and stored the pellet on ice. We then induced protein expression with arabinose at a final concentration of 0.02% and grew the

- 52 -

culture for an additional 4 hours. We centrifuged an aliquot of this arabinose-induced sample at maximum speed, removed the supernatant and placed on ice. We resuspended the uninduced and arabinose-induced pellets in sample buffer, boiled the sample for 5 minutes and analyzed by denaturing polyacrylamide (SDS-PAGE) gel and stained with Coomassie blue. We observed that the 71 kDa TR-env protein was the major protein found in the *E. coli* cells after arabinose induction.

10 [0165] We lysed the induced *E. coli* cells by sonication, centrifuged, and purified the TR-env protein in the soluble supernatant with ThioBond™ phenylarsinine oxide resin (Invitrogen) following the manufacturer's protocol. The TR-env protein was bound to this affinity
15 resin in a batch mode and then eluted with increasing concentrations of beta-mercaptoethanol. We ran the fractions on a denaturing polyacrylamide (SDS-PAGE) gel and stained with Coomassie blue. The procedure yielded highly purified recombinant TR-env fusion protein
20 (FIG. 5).

[0166] In immunoblots, the TR-env protein was recognized by both anti-thioredoxin antibody (Invitrogen) and human sera from two individuals seropositive for antibodies to WN virus. The purified TR-env fusion
25 protein, thus, contained an epitope recognized by antibodies induced by a natural WN virus infection.

[0167] Thioredoxin expressed from the pBAD/TOPO™ ThioFusion® expression vector was used as a negative control protein. The 16 kDa thioredoxin protein was
30 expressed in *E. coli* and purified using ProBond™ metal-chelating affinity resin as described for the TR-env protein. Purified thioredoxin was recognized in immunoblots only by anti-thioredoxin antibody

- 53 -

(Invitrogen) and not by human sera from two individuals seropositive for antibodies to WN virus.

[0168] Alternatively, we expressed and purified the WN virus envelope protein as a fusion protein with maltose binding protein (MBP). We amplified nucleotides 1-1218 of the WN virus E protein by PCR using the following primers which contain *EcoRI* and *PstI* restriction sites to facilitate subcloning: 5'-GAATTCTTCAACTGCCTTGGAATGAGC-3' (SEQ ID NO: 6) and 5'-CTGCAGTTATTTGCCAATGCTGCTTCC-3' (SEQ ID NO: 7). We digested the PCR product with *EcoRI* and *PstI* and cloned the resulting fragment into the pMAL[™]-c2X vector (New England Biolabs, Beverly, MA), creating a recombination fusion to the *E. coli* *malE* gene which encodes the maltose-binding protein (MBP). We grew DH5 α containing the resulting plasmid to a concentration of 2×10^8 cells/ml and added isopropyl-D-thiogalactopyranoside (IPTG) to a final concentration of 0.3 mM. We then incubated this culture for 2 hours at 37°C, harvested the cells by centrifugation at 4,000 x g for 20 minutes and, lysed the cells by freezing overnight at -20°C and then sonicating the cells for 10 minutes. We confirmed expression of a soluble 82 kDa MBP-env fusion protein in *E. coli* by SDS-PAGE analysis and Coomassie blue staining. We then purified the MBP-env fusion protein using a maltose-affinity column according to the manufacturer's instructions. We obtained 3 mg of protein from 250 ml of cell culture. We also purified MBP as a control following the same protocol.

[0169] We then used the MBP-env fusion protein to analyze sera for the presence of antibodies to the E protein. We boiled 2 μ g of MBP-env fusion protein or MBP (control) protein in SDS-PAGE sample buffer (BioRad) containing 2% β -mercaptoethanol, ran the samples on a 10% SDS-PAGE gel and transferred the proteins to

- 54 -

nitrocellulose membrane using a semi-dry electrotransfer apparatus (Fisher Scientific). We then probed the nitrocellulose membrane with sera from 5 patients with confirmed WN virus infection and sera from uninfected individuals. We incubated the membrane with the sera (1:100 dilution) for 1 hour, washed the membrane 3 times with Tris-buffered saline with Tween 20 (TBST) and added alkaline phosphatase-conjugated goat anti-human IgG (1:1,000 dilution; Sigma). We developed the blots with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (Kirkegaard & Perry Laboratories). The MBP-env fusion protein detected IgG antibodies to the E protein in western blots with sera from 5 humans with confirmed WN virus infection, but not in the control human sera. In essentially identical experiments, the MBP-env fusion protein also detects IgM antibodies to the E protein in western blots with sera from 5 humans with confirmed WN virus infection, and IgG and IgM antibodies with sera from 10 horses with confirmed WN virus infection, but not in control human or horse sera.

Example IV - Validation of the Mouse model of WN virus infection

[0170] Previous studies demonstrated that mice can be infected with the WN virus [A.H. Eldadah, et al., *Am J Epidemiol*, 86, pp. 765-75 (1967); S. Haahr, *Acta Pathol Microbiol Scand*, 74, pp. 445-47 (1968); L.P. Weiner, et al., *J Hyg (Lond)*, 68, pp. 435-46 (1970); A.J. Johnson and J.T. Roehrig, *J Virol*, 73, pp. 783-6 (1999)]. All of these experiments used isolates of WN virus that have been recovered outside of the United States. We have extended these studies using WN virus isolates from Connecticut.

- 55 -

[0171] Following established protocols, we inoculated six-week-old C3H/HeN (C3H) mice intraperitoneally with a range of dilutions of the 2741 WN virus isolated as described in Example I. These dilutions corresponded to 5 10^{-2} - 10^6 plaque-forming units of WN virus. We monitored the mice over a period of two weeks. The majority of the mice died after approximately 1-2 weeks. At 15 days surviving mice were sacrificed, and the blood, liver, spleen, and brain cultured for WN virus. Experiments 10 used groups of five mice. We observed significant mortality at inoculation doses down to 1 plaque forming unit (10^0) (Figure 8). Our results showed that WN virus isolate 2741 from Connecticut is able to infect mice and that the course of infection is similar to murine disease 15 that has been described for WN virus isolates from outside the U.S.

Example V - Active immunization with purified TR-env and MBP-E protein

[0172] We immunized two groups of three-week-old 20 female C3H mice were immunized subcutaneously with 20 μ g of purified TR-env or thioredoxin (TR) as a control antigen in Freund's adjuvant (complete for the first immunization on day 0; incomplete for booster immunizations on day 7 and day 14). We used an 25 accelerated immunization schedule in this experiment because mice become less susceptible to West Nile virus encephalitis as they age. On day 21, we bled the mice, recovered the sera and conducted ELISA and immunofluorescence assays to determine the anti-envelope 30 protein antibody titer. Immunized mice developed high titer anti-envelope protein antibodies.

[0173] We also actively immunized C3H mice with 20 μ g MBP-env protein, or MBP protein as a negative control, as

described above. Mice immunized with the MBP-env protein developed high titers of antibodies to the WN virus env protein. We then challenged mice with approximately 100 plaque-forming units of WN virus isolate 2741. We
5 observed 100% survival of mice immunized with MBP-env protein compared to only 10% survival of mice immunized with MBP.

[0174] We also actively immunize with the WNE 121-139 or the WNE 288-301 peptides and determine antibody titers
10 as described above. We further challenge mice immunized with MBP-env, the WNE 121-139 peptide or the WNE 288-301 peptide with WN virus 2741 as described above and determine the degree of protection.

[0175] For an initial immunoprotection study, we
15 challenged mice immunized with WN TR-env fusion protein or TR control protein as described above with 2.5×10^6 plaque-forming units of WN virus isolate 2741 (intra-peritoneally). Mice were monitored daily for morbidity and mortality, and were euthanized if showing signs
20 indicative of death (i.e. inappetence, coma, dehydration, or partial paralysis). The effects of WN virus infection became evident after seven days of infection. By day 15, two of five TR-env immunized mice survived compared to only one of the control mice. As indicated by the
25 survival curves shown in Figure 6, the control mice are more susceptible to the pathological effects of WN virus compared to mice immunized with WN TR-env fusion protein. This challenge experiment demonstrates that vaccination with envelope fusion protein can alter susceptibility to
30 WN virus and is at least partially protective.

[0176] Having shown that TR-env elicits a partially protective immune response, we then optimize the protective response by varying the immunization conditions. For example, we alter the immunization

- 57 -

schedule, adjuvants and dosing, or routes of administration and challenge dose. For example, as described in Example VII, challenge with 10 plaque-forming units in a passively immunized animal produced 80% protection. Those of skill in the art would recognize that envelope protein from other strains of WN virus can be used as the immunogen in the methods described above.

Example VI - Antibodies generated to purified TR-env protein recognize synthetic peptides

A. Selection of peptides representing epitopes recognized by antibodies that recognize the envelope protein

[0177] We prepared a structural model of the WN virus envelope protein using the 3D-PSSM Protein Fold Recognition (Threading) Web Server V 2.0 [L.A. Kelley et al., *J Mol Biol*, 299, pp. 499-520 (2000)]. We compared the WN virus structural model to a structural model of the tick-borne encephalitis (TBE) envelope glycoprotein protein soluble domain [F.A. Rey et al., *Nature*, 375, pp. 291-8 (1995)] using a three-dimensional position-specific scoring matrix (3D-PSSM). We used the model to design two synthetic peptides from WN virus envelope protein for testing as a vaccine. Peptide WNE 121-139 has sequence homology to a heparan sulfate binding domain found in the dengue virus envelope protein. Binding to target cells via heparan sulfate has been reported to play a role in flavivirus infectivity [Y. Chen et al., *Nature Med*, 3, pp. 866-871 (1997)]. An antibody that binds the WNE 121-139 peptide, thus, could alter WN virus binding to heparan sulfate and inhibit or prevent infection of target cells.

- 58 -

[0178] Based on the structural model, peptide WNE 288-301 appears to be a surface-exposed hinge region between domains I and II of the WN virus envelope protein. We also synthesized a negative control peptide, which we
5 designated "random 288-301." The control peptide has the same amino acid content as WNE 288-301, but in randomized sequence except for the N-terminal cysteine.

[0179] Peptides were synthesized on a Rainin Symphony™ instrument at a 50 μmol scale, purified by reverse phase
10 HPLC and analyzed by MALDI mass spectroscopy. The peptide synthesis, purification and analysis were performed by the Keck Foundation Biotechnology Resource Laboratory at Yale University. The three peptides were conjugated to carrier proteins using Imject® maleimide
15 activated ovalbumin and KLH (Pierce) following the manufacturer's instructions.

B. Synthetic peptides are recognized by antibody generated in response to immunization with purified Tr-env

20 [0180] We tested sera from mice immunized with purified WN virus TR-env fusion protein as described in Example V for the presence of antibodies specific for the WNE 121-139 (SEQ ID: 3) peptide in an ELISA using the peptide as antigen (FIG. 7). Pooled antisera from TR-env
25 immunized mice recognized peptide WNE-121-139 (SEQ ID: 3) conjugated to ovalbumin, but did not recognize the control peptide random-288-301 (SEQ ID: 5) or unconjugated ovalbumin. Pooled antisera from control thioredoxin immunized mice were negative in ELISAs with
30 these antigens. Thus, immunization with the WN TR-env protein elicits antibodies that specifically recognize the peptide.

- 59 -

Example VII - Passive Immunization

[0181] We prepared antiserum from C3H/HeN mice by immunizing in the back with 20 µg TR-env or TR (control) in 200 µl complete Freund's adjuvant. We then boosted
5 the mice with 20 µg of antigen in 200 µl incomplete Freund's adjuvant at 2 and 4 weeks. We bled the mice ten days after the final immunization and stored the antisera at -20°C. We then passively immunized mice by
10 intradermally injecting 100 µl of antisera (diluted 1:5 in PBS) that was pooled from 5 mice that had been actively immunized with the TR-env fusion protein. We also passively immunized a group of mice with TR antisera (control). We then challenged the passively immunized animals with approximately 10 plaque-forming units of the
15 2741 WN virus isolate 24 hours after immunization and evaluated immunity to WN virus as described in Example V. As shown in Figures 9 and 10, we observed protection of mice passively immunized with antisera directed to the E protein relative to control. This challenge experiment
20 demonstrates that passive immunization with antisera to the envelope fusion protein can alter susceptibility to WN virus and is substantially protective.

Example VIII - Analysis of Cross Protection

25 [0182] To determine the degree of protection against other WN virus isolates afforded by immunization with a polypeptide from one WN virus isolate (different WN virus isolates include, for example, WNV-NY1999, WNV-Cm-CT99, WNV-Crow-NJ99, WNV-Crow-NY99, WNV-C.pipiens-NY99, WNV-
30 Eq.-NY99, WNV-HB709-NY99, WNV-HB743-NY99, WNV-USAMRIID99), we immunize mice with a polypeptide or fusion protein as described in Example V. We then

- 60 -

challenge the immunized mice with a different WN virus isolate and monitor the mice as described in Example V. Alternatively, we perform a western blot using antibodies or antisera against one isolate of WN virus to detect
5 polypeptides of another isolate.

Example IX - Preparation of Protective Monoclonal Antibodies to WN Virus Polypeptides

[0183] To prepare antibodies to a WN virus polypeptide in one of the compositions of the invention, we immunize
10 C3H mice subcutaneously with TR-env in complete Freund's adjuvant and boost with the same amount in incomplete Freund's adjuvant at 7 and 14 days. We immunize control animals in the same manner with either TR or bovine serum albumin (BSA).

15 [0184] Seven days after the last boost, we collect sera from the immunized animals and use it to hybridize to Western blots of SDS-PAGE gels of extract from WN virus-infected Vero cells or to the recombinant polypeptide. We detect binding with alkaline phosphatase
20 goat-anti-mouse antibody developed with nitroblue tetrazolium and 5-bromo-4-chloroindoyl phosphate. Alternatively, we use the ECL™ kit (Amersham, Arlington Heights, IL) in which the secondary antibody, horseradish peroxidase-labeled goat anti-mouse antibody, can be
25 detected.

[0185] To prepare a monoclonal antibody, we recover antibody producing cells from the spleens of the immunized animals, fuse the antibody producing cells with immortalized cells to produce hybridomas according to the
30 methods of Kohler and Milstein. We screen the resulting hybridomas for specific binding to the Tr-env fusion protein described in this invention. Those of skill in the art will appreciate that polyclonal and monoclonal

- 61 -

antibodies specific of the other WN virus polypeptides in the compositions of the invention may be prepared using the methods described herein.

[0186] A protective antibody, including a monoclonal
5 antibody, may be identified, for example, by passively immunizing mice with the antibody, challenging the mice with WN virus and monitoring infection in the mice.

[0187] All publications and patent applications cited
10 in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of
15 understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

- 62 -

We claim:

1. A composition for treating, inhibiting or preventing West Nile (WN) virus infection or disease, comprising one or more isolated and substantially purified WN virus polypeptides or an immunogenic fragment thereof and a pharmaceutically acceptable carrier.
2. The composition according to claim 1, wherein the WN virus polypeptide is a WN virus envelope (E) protein or an immunogenic fragment thereof.
3. The composition according to claim 2, wherein the WN virus E protein or fragment is from isolate WN 2741.
4. The composition according to claim 3, wherein the amino acid sequence of the WN virus E protein or fragment is the amino acid sequence encoded by the E protein encoding DNA sequence of Genbank accession No. AF 206518, or a fragment thereof.
5. The composition according to claim 1, wherein said WN virus polypeptide or fragment comprises a sequence with homology to a heparan sulfate binding domain.
6. The composition according to claim 4, wherein said fragment is the WNE 121-139 peptide (SEQ ID NO: 3).
7. The composition according to claim 4, wherein said fragment is the WNE 288-301 peptide (SEQ ID NO: 4).
8. The composition according to claims 6 or 7, wherein said WN virus peptide is joined to keyhole limpet hemocyanin (KLH).

- 63 -

9. The composition according to claim 1, further comprising an adjuvant.

10. The composition according to any one of claims 1-7 and 9, wherein said WN virus polypeptide or fragment is
5 part of a fusion protein.

11. The composition according to claim 10, wherein said fusion protein comprises thioredoxin or maltose binding protein.

12. The composition according to claim 2 comprising at
10 least one additional WN virus polypeptide or an immunogenic fragment thereof.

13. The composition according to claim 12, wherein said additional WN virus polypeptide or fragment is from the same isolate of WN virus as the E protein.

14. The composition according to claim 12, where said
15 additional WN virus polypeptide or fragment is from a different isolate of WN virus than the E protein.

15. The composition according to claim 12, wherein said additional WN virus polypeptide is selected from the
20 group consisting of: a capsid (C) protein, a membrane (M) protein and a non-structural (NS) protein, or an immunogenic fragment thereof.

16. The composition according to claim 15 wherein said additional WN virus polypeptide is an NS protein or an
25 immunogenic fragment thereof.

17. The composition according to claim 2 comprising at least one additional WN virus E polypeptide, or an

- 64 -

immunogenic fragment thereof, wherein said WN virus E polypeptides are from different isolates of WN virus.

18. The composition according to any one of claims 1-17, further comprising an immunogenic component from another
5 arthropod-borne pathogen.

19. The composition according to claim 18, wherein said arthropod-borne pathogen is a flavivirus.

20. A composition comprising an antibody that specifically binds a WN virus polypeptide or an
10 immunogenic fragment thereof, wherein said antibody inhibits or lessens the severity of WN virus infection or disease.

21. The composition according to claim 20, wherein said antibody specifically binds a WN virus E protein or a
15 fragment thereof.

22. An antibody or an antigen-binding portion thereof that specifically binds a WN virus E protein or an immunogenic fragment thereof.

23. The antibody or an antigen-binding portion thereof
20 according to claim 22, wherein the E protein or fragment is from WN virus isolate 2741.

24. The antibody or an antigen-binding portion thereof according to claim 23, wherein said fragment is WNE 121-139 peptide (SEQ ID NO: 3).

25 25. The antibody or an antigen-binding portion thereof according to claim 23, wherein said fragment is WNE 288-301 peptide (SEQ ID NO: 4).

- 65 -

26. The antibody or an antigen-binding portion thereof according to claim 23, which specifically binds a heparan sulfate binding domain of a WN virus E protein.

27. The antibody or an antigen-binding portion thereof
5 according to any one of claims 22-26, which is a monoclonal antibody.

28. The antibody or an antigen-binding portion thereof according to any one of claims 22-27, wherein said antibody or antigen-binding portion thereof inhibits or
10 lessens the severity of WN virus infection or disease.

29. An antibody or an antigen-binding portion thereof produced by immunizing a non-human mammal with a polypeptide according to any one of claims 43-49.

30. A diagnostic kit comprising at least one polypeptide
15 according to any one of claims 43-49.

31. The kit according to claim 30, wherein said E protein or fragment is from WN virus isolate 2741.

32. The kit according to claim 31, wherein the amino acid sequence of the WN virus E protein or fragment is
20 the amino acid sequence encoded by the E protein encoding DNA sequence of Genbank accession No. AF 206518, or a fragment thereof.

33. The kit according to any one of claims 30-32, wherein said E protein or fragment is part of a fusion
25 protein.

34. A nucleic acid molecule comprising a nucleotide sequence encoding a fusion protein, said fusion protein

- 66 -

comprising a WN virus E protein or an immunogenic fragment thereof.

35. The nucleic acid molecule according to claim 34, wherein said E protein fragment is the WNE 121-139 peptide (SEQ ID NO: 3).

36. The nucleic acid molecule according to claim 34, wherein said E protein fragment is the WNE 288-301 peptide (SEQ ID NO: 4).

37. The nucleic acid molecule according to any one of claims 34-36, wherein the nucleic acid sequence is operably linked to an expression control sequence.

38. A host cell comprising the nucleic acid molecule according to any one of claims 33-37.

39. A method for producing a polypeptide encoded by a nucleic acid molecule according to any one of claims 33-37, comprising the step of culturing the host cell according to claim 38.

40. A method for treating, inhibiting or preventing WN virus infection or disease comprising the step of administering a compositions according to any one of claims 1-19.

41. A method for treating, inhibiting or preventing WN virus infection or disease comprising the step of administering a composition according to claim 20 or 21.

42. A method for treating, inhibiting or preventing WN virus infection or disease comprising the step of

- 67 -

administering an antibody or an antigen-binding portion thereof according to any one of claims 22-29.

43. An isolated and purified polypeptide comprising a WN virus envelope (E) protein or an immunogenic fragment
5 thereof.

44. The polypeptide according to claim 43, which is a fusion protein.

45. An isolated polypeptide, consisting essentially of a WN virus envelope (E) protein or an immunogenic fragment
10 thereof.

46. An isolated polypeptide, consisting of a WN virus envelope (E) protein or an immunogenic fragment thereof.

47. The polypeptide according to any one of claims 43-46, wherein said WN virus E protein is from WN virus
15 isolate 2741.

48. The polypeptide according to any one of claims 43-47, wherein said polypeptide is the WNE 121-139 peptide (SEQ ID NO: 3).

49. The polypeptide according to any one of claims 43-47, wherein said polypeptide is the WNE 288-301 peptide (SEQ ID NO: 4).
20

50. A method for detecting WN virus infection comprising the step of contacting a sample from a subject suspected of having said infection with an isolated and
25 substantially purified polypeptide according to any one of claims 43-49.

- 68 -

51. A method for detecting a protective immune response in a subject comprising the step of contacting a sample from said subject with a polypeptide according to any one of claims 43-49.

5 52. A method for detecting WN virus infection comprising the step of contacting a sample from a subject suspected of having said infection with the antibody or an antigen-binding portion thereof according to any one of claims 22-29.

10 53. A method for treating, inhibiting or preventing WN virus infection or disease comprising the step of administering a polypeptide according to any one of claims 43-49.

54. A method for identifying a protective WN virus polypeptide comprising the steps of:

15 a) immunizing a C3H mouse with an WN virus polypeptide or fragment thereof;

b) challenging the immunized mouse produced in step a) with WN virus; and

20 c) identifying a WN virus polypeptide that confers protection against WN virus infection or disease.

55. A method for identifying an protective antibody that specifically binds a WN virus polypeptide, comprising the steps of:

25 a) passively immunizing a C3H mouse with an antibody that specifically binds a WN virus polypeptide;

b) challenging the immunized mouse produced in step a) with WN virus; and

c) identifying an antibody that confers protection

30 against WN virus infection or disease.

Peptide 1
"WNE 288-301"
N terminus – C-R-V-K-M-E-K-L-Q-L-K-G-T-T – C terminus
14 amino acid residues

FIG. 1

Peptide 2

“Random 288-301”

N terminus – C-Q-L-L-M-R-E-V-K-T-G-T-K-K – C terminus

14 amino acid residues

FIG. 2

Peptide 3**“WNE 121-139”****N terminus – C-S-T-K-A-I-G-R-T-I-L-K-E-N-I-K-Y-E-V – C terminus****19 amino acid residues**

FIG. 3




FIG. 4




Fig 3. Recombinant TR-env protein. Purified Tr-env protein was analyzed by SDS-PAGE and coomassie blue staining. MW markers: 106, 78, 50, 35, 28, & 20 kDa

FIG. 5





FIG. 6



mouse serum(TR-EV1) day 21

FIG. 7




FIG. 8




FIG. 9




FIG. 10

SEQUENCE LISTING

<110> Yale University
L2 Diagnostics
Erol Fikrig
Raymond A. Koski
Tian Wang

<120> Compositions and Methods Comprising West Nile Virus
Polypeptides

<130> YU-108/PCT

<150> US 60/275,025

<151> 2001-03-12

<150> US 60/281,947

<151> 2001-04-05

<160> 7

<210> 1

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<223> Oligonucleotide primer

<400> 1

gactgaagag ggcaatgttg agc

23

<210> 2

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<221> Modified_base

<222> 16

<223> Oligonucleotide primer with y residue at position 16

<400> 2

gcaataactg cggacytctg c

21

<210> 3

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Polypeptide fragment of West Nile Virus E Protein

<400> 3

Cys Arg Val Lys Met Glu Lys Leu Gln Leu Lys Gly Thr Thr
1 5 10

<210> 4

<211> 14

<212> PRT

<213> Artificial sequence

<220>

<223> Polypeptide fragment of West Nile Virus E Protein

<400> 4

Cys Gln Leu Leu Met Arg Glu Val Lys Thr Gly Thr Lys Lys
1 5 10

<210> 5

<211> 19

<212> PRT

<213> Artificial sequence

<220>

<223> Polypeptide fragment of West Nile Virus E Protein

<400> 5

Cys Ser Thr Lys Ala Ile Gly Arg Thr Ile Leu Lys Glu Asn Ile Lys
1 5 10 15

Tyr Glu Val

<210> 6

<211> 27

<212> DNA

<213> Artificial sequence

<220>

<223> Oligonucleotide primer

<400> 6

gaattcttca actgccttgg aatgagc

27

<210> 7

<211> 27

<212> DNA

<213> Artificial sequence

<220>

<223> Oligonucleotide primer

<400> 7

ctgcagttat ttgccaatgc tgcttcc

27

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072036 A3

(51) International Patent Classification⁷: **A61K 39/12**

(21) International Application Number: PCT/US02/09036

(22) International Filing Date: 11 March 2002 (11.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/275,025 12 March 2001 (12.03.2001) US
60/281,947 5 April 2001 (05.04.2001) US

(71) Applicants (for all designated States except US): **YALE UNIVERSITY** [US/US]; 451 College Street, New Haven, CT 06520 (US). **L2 DIAGNOSTICS, LLC** [US/US]; P.O. Box 9728, New Haven, CO 06536-0728 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FIKRIG, Erol** [US/US]; 101 Coventry Way, Guilford, CT 06437 (US). **KOSKI, Raymond, A.** [US/US]; 7 Meetinghouse Lane, Old Lyme, CT 06371 (US). **WANG, Tian** [CN/US]; 550 Prospect Street #2, New Haven, CO 06511 (US).

(74) Agents: **HALEY, James, F., Jr.** et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS COMPRISING WEST NILE VIRUS POLYPEPTIDES

(57) Abstract: This application is directed to compositions and methods comprising isolated and purified West Nile virus polypeptides and immunogenic fragments thereof, nucleic acid molecules encoding them and antibodies specific for such polypeptides or fragments. Such polypeptides and fragments, fusion proteins comprising them and antibodies are useful as vaccines to treat, inhibit or prevent West Nile virus infection or disease, to detect West Nile virus infection and to monitor the course of disease or immunization.



WO 02/072036 A3



BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:

22 May 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/09036

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39/12

US CL : 424/217.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/217.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P --- Y, P	WANG et al. West Nile virus envelope protein: role in diagnosis and immunity. Annals New York Academy of Science. December 2001, Vol. 951, pages 325-327, see entire document.	1-7, 9, 20-27, 41, 43-47, 55 ----- 8, 12-17
X, P --- Y, P	WANG et al. Immunization of mice against West Nile virus with recombinant envelope protein. Journal of Immunology. 2001, Vol. 167, pages 5273-5277, see entire document.	1-7, 9, 20-27, 34-37, 41, 43-47, 54 ----- 8, 12-17
Y, P	KRAMER et al. West Nile virus in the western hemisphere. Current Opinion in Infectious Diseases. 2001, Vol. 14, pages 519-525, see page 522-523.	1-3, 8, 9, 12-17, 20-22, 26, 27, 34, 41, 43-46, 54, 55
Y	MATHEWS et al. T-helper cell and associated antibody response to synthetic peptides of the E glycoprotein of Murray Valley Encephalitis virus. Journal of Virology. October 1991, Vol. 65, No. 10, pages 5141-5148, see table 1 and figure 5.	1, 2, 5, 8, 9, 12-17, 43, 45, 46, 54
Y	US 5,494,671 A (LAI et al.) 27 February 1996 (27.02.1996), columns 1, 2 and 5.	1, 2, 5, 8, 9, 12-17, 34, 43, 45, 46, 54



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

27 November 2002 (27.11.2002)

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Date of mailing of the international search report

Authorized officer

Ulrike Winkler, Ph.D.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,486,473 A (FUJITA et al.) 23 January 1996 (23.01.1996), column 1 and 2.	1, 34, 37, 43
Y	LANCIOTTI et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science. 17 December 1999, Vol. 286, pages 2333-2337, see figure 1 and table 2.	1, 2, 5, 8, 9, 12-17, 34, 37, 43-46
Y	ANDERSON et al. Isolation of West Nile virus from mosquitoes, crows and a Cooper's hawk in Connecticut. Science. 17 December 1999, Vol. 286, pages 2331-2333, see entire document.	1-4, 34-37
Y	PRICE et al. Live and inactivated vaccines of group B arboviruses: role of neutralizing antibody and serum protective factor. Nature. 1969, Vol. 222, pages 1294-1295, see entire document.	1, 54

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/09036

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claim Nos.: 10, 11, 18, 19, 28-33, 38-40, 42, 48-53
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-9, 12-17 and 43-47, drawn to a composition comprising West Nile virus (WNV) envelope polypeptide and method of treating using the polypeptide.

Group II, claims 20-27 and 41-42, drawn to a composition of antibodies to WNV E protein and a method of treating using the antibodies.

Group III, claims 34-39, drawn to WNV nucleic acid and method of making WNV polypeptide with the nucleic acid.

Group IV, claim 54, drawn to a method of detecting a protective polypeptide.

Group V, claim 55, drawn to a method of detecting a protective antibody.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The asserted special technical feature is a composition for treating, inhibiting or preventing WNV infection comprising an isolated WNV polypeptide or immunogenic fragment thereof. However, this feature lacks novelty and inventive step in view of Lai *et al* (US Patent 5,494,671) which teaches truncated flavivirus envelope proteins that can be used as vaccines against flavivirus infections. Lai is silent on WNV envelope vaccines, but discloses the similarity of structure between flaviviruses having three proteins: C, M and E. Lai says that E is the major virion antigen responsible for virus neutralization and antigenic properties. It would have been obvious to substitute WNV for Dengue in Lai's vaccine because Lai teaches the similarity of structure between flaviviruses (cols. 1-2). Further, one would have been motivated by the need for a WNV vaccine given the frequent incidents of WNV starting in 1999 in North America. One would have had a reasonable expectation of success given the immunogenic nature of the E protein of flaviviruses.

The WNV proteins are distinct from the antibodies to WNV because they are structurally different and have different functions. The proteins are distinct from the nucleic acid encoding them because they are chemically and structurally different.

Continuation of B. FIELDS SEARCHED Item 3:
WEST, DERWENR, STN-BIOSIS, MEDLINE, EMBASE
STIC SEQ ID NO: 3 and 4